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Synopsis...
A comprehensive summary of the work to be incorporated in the thesis entitled
“DESIGN AND SYNTHESIS OF CHEMICAL ENTITIES OF
THERAPEUTIC INTEREST” has been described as under :
STUDIES ON 1,3-DIARYL PYRAZOLES :
Pyrazole nucleus are endowed with a variety of biological activities such as
antiinflammatory, antitumor, fungicidal, antitubercular, amoebicidal, herbicidal,
anticonvulsant, hypnotic, CNS depressant, plant growth regulatory activity etc. Our
efforts are focused on introduction of chemical diversity in the molecular frame work
in order to synthesizing active molecule of widely different composition.
Considering the increasing importance of pyrazole nucleus, the synthesis of
some novel  chalcones,  pyrazolines,  cyanopyridines,  cyanopyridones,
aminopyrimidines, cyclohexenones, indazoles, thiazolidinopyrimidines and
imidazolinones bearing 1,N-phenyl-3-[p-(methylthio)phenyl]-4-formyl pyrazole
nucleus which have been described as under.
PART - I : STUDIES ON CHALCONES
The chalcones containing an active keto-ethylenic linkage are well known
intermediates in the synthesis of heterocyclic compounds. They exhibiting various
biological activities like antibacterial, antifungal diuretic, anticancer, antitubercular,
herbicidal etc. they are suppose to find applicable in brightening agents,
photosensitive materials natural pigments, polymerization catalyst etc. keeping this
in view, it was considerable worthwhile to synthesize some new chalcones and its
derivatives which have been described as under.
Design and Synthesis ...
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Synopsis...
SECTION - I : Synthesis and biological evaluation of 1-Aryl-3-{1',N-
phenyl-3'-[p-(methylthio)phenyl]-pyrazol-4'-yl}-2-
propene-1-ones
The chalcones of Type (I) have been undertaken by the condensation of
1,N-phenyl-3-[p-(methylthio)phenyl-4-formyl pyrazole with different aryl ketones
in presence of 40% NaOH.
PART - II : STUDIES ON PYRAZOLYL PYRAZOLINES
Among a wide variety of heterocycles that have been explored for developing
biologically active molecules like pyrazolines have played all important role in
medicinal chemistry. Pyrazoline derivatives are associated with wide range of
biological activities like antimicrobial, antitubercular, analgesic and antiinflammatory.
In order to achieving better drug potential, we have synthesize some new pyrazoline
derivatives, which have been described as under.
SECTION - I : Synthesis and biological evaluation of 3-Aryl-5-{1',N-
phenyl-3' - [p-(methylthio)phenyl]-pyrazol-4' -yl}-
pyrazolines
          Type- (I)       R = Aryl
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Synopsis...
Pyrazoline derivatives of Type (II) have been prepared by the condensation
of chalcones of Type (I) with hydrazine hydrate.
SECTION - II : Synthesis and biological evaluation of 1,N-Acetyl-3-aryl-
5-{1',N-phenyl-3'-[p-(methylthio)phenyl]-pyrazol-4'-yl}-
pyrazolines
The pyrazoline derivatives of Type (III) have been undertaken by the reaction
of chalcones of Type (I) with hydrazine hydrate in glacial acetic acid.
SECTION - III : Synthesis and biological evaluation of 1,N-Phenyl-3-
aryl-5-{1',N-phenyl-3'-[p-(methylthio)phenyl]-pyrazol-4'-
yl}-pyrazolines
Pyrazolines of Type (IV) have been synthesized by the condensation of
chalcones of Type (I) with phenyl hydrazine in presence of basic catalyst like
piperidine.
Type- (III) R = Aryl
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Synopsis...
PART - III : STUDIES ON CYANOPYRIDINES
Cyanopyridine derivatives have attracted considerable attention in view
of their great therapeutic importance as antidiabetic, hypertensive, antibacterial,
anticonvulsant and antifungal agents. To approach this goal, preparation of some
novel cyanopyridine derivatives have been undertaken as under.
SECTION - I : Synthesis and biological evaluation of 2-Amino-3-
cyano-4-{1',N-phenyl-3'-[p-(methylthio)phenyl]-pyrazol-
4'-yl}-6-aryl-pyridines
The cyanopyridine derivatives of Type (V) have been prepared by the
condensation of chalcones of Type (I) with malononitrile and ammonium acetate.
PART - IV : STUDIES ON CYANOPYRIDONES
Cyanopyridone ring system have a prominent feature in medicinal chemistry
and possess biological activities such as analgesic, insecticidal, antibacterial,
antidiabetic, anticonvulsant etc. In view of these facts, it was contemplated to
synthesize cyanopyridone derivatives which have been described as under.
SECTION - I : Synthesis and biological evaluation of 3-Cyano-4-{1',N-
phenyl-3'-[p-(methylthio)phenyl]-pyrazol-4'-yl}-6-aryl-
1,2-dihydro-2-pyridones
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Synopsis...
Cyanopyridones of Type (VI) have been prepared by the reaction of
chalcones of Type (I) with ethylcyanoacetate and ammonium acetate.
PART - V :   STUDIES ON INDAZOLES
 Indazole derivatives have drawn considerable attention in view of their great
pharmacological activities like antifungal, cardiovascular, sedative and antibacterial.
To approach this goal, synthesis of some new indazole derivatives have been de-
scribed as under.
SECTION - I   : Synthesis and biological evaluation of Ethyl-6-{1',N-
phenyl-3'-[p-(methylthio)phenyl]-pyrazol-4'-yl}-2-oxo-4-
arylcyclohex-3-ene-1-carboxylates
Cyclohexenones  of  Type  (VII )  have  been  prepared  by  the
cyclocondensation of chalcones of Type (I) with ethylacetoacetate in the presence
of   basic catalyst K2CO3.
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Synopsis...
SECTION-II : Synthesis and biological evaluation of 4-{1',N-Phenyl-
3'-[p-(methylthio)phenyl]-pyrazol-4'-yl}-6-aryl-2,3a,4-5-
tetrahydro-3H-indazol-3-ones
Indazole derivatives of  Type (VIII) have been synthesized by the
cyclocondensation of cyclohexenones of  Type (VII) with  hydrazine hydrate.
PART - VI : STUDIES ON AMINOPYRIMIDINES
It has been reported that pyrimidine derivatives are associated with various
biological activities like antifungal, antibacterial, antitubercular, herbicidal etc. In order
to develop medicinally important compounds, it was considered of interest to
synthesize some new aminopyrimidines shown as under.
SECTION-I : Synthesis and biological evaluation of 2-Amino-4-
{1',N-phenyl-3'-[p-(methylthio)phenyl]-pyrazol-4'-yl}-6-
aryl-pyrimidines
   Type- (VIII)        R = Aryl
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Synopsis...
Pyrimidine derivatives of Type (IX) have been prepared by the reaction of
chalcones of Type (I) with guanidine hydrochloride.
PART - VII : STUDIES ON THIAZOLIDINONES
It has been reported that thiazolidinone derivatives are associated with wide
range of biological activities like antitumor, antileprosy, antitubercular, antibacterial
etc. In order to develop medicinally important compounds, we have synthesized
some new thiazolidinones shown as under.
SECTION - I : Synthesis and biological evaluation of 2-Aryl imino-3,N-
aryl-5-{1' ,N-phenyl-3' -[p-(methylthio)phenyl]-4 ' -
pyrazolylmethino}-4-thiazolidinones
Thiazolidinone derivatives of Type (X) have been prepared by condensation
of 1-phenyl-3-[p-(methylthio)phenyl-4-formyl pyrazole with different thiazolidinones
in glacial acetic acid.
PART - VIII : STUDIES ON PYRIMIDINONES
In view of powerful biological activities shown by cyano pyridones, like
antitumor, antimicrobial, analgesics, antiinflammatory, herbicidal and antitubercular.
It was worthwhile to synthesized some novel cyano pyridone derivatives possessing
better biological active value with least side effect, which have been described as
under.
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Synopsis...




The oxopyrimidine derivatives of Type (XI) have been synthesized by the
condensation of thiazolidinones of Type (X) with urea, in presence of HCl as catalyst.
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Synopsis...
The thiopyrimidine derivatives of Type (XII) have been synthesized by the
condensation of thiazolidinones of Type (X) with thiourea, in presence of HCl as
catalyst.
PART - IX : STUDIES ON IMIDAZOLINONES
Imidazolidinone derivatives have been found to be potent drug in
pharmaceutical and possess a wide range of biological activities such as
antihistamine, anticonvulsant, hypnotic, antiinflammatory, sedative and
antithyroid. In order to explore the activities associated with the nucleus, we
synthesized some new imidazolinones shown as under.
SECTION - I : Synthesis and biological evaluation of 1,N-Aryl-2-alkyl/
aryl-4-{1',N-phenyl-3'-[p-(methylthio)phenyl]-4'-pyrazolyl
methino}-imidazolin-5-ones
Imidazolinone derivatives of Type (XIII) have been synthesized by the reaction
of azalactone with different aryl amines in pyridine.
The constitution of all above products has been supported by elemental
analysis and spectral studies like IR, 1H NMR and Mass spectroscopy. The purity
of the compounds synthesized was checked by TLC.
   R = Alkyl/Aryl











Design and Synthesis ...
10
Synopsis...
In vitro study on multiple biological activities:
[1] Selected compounds have been evaluated for their in vitro biological assay
like antitubercular activity towards a strain of Mycobacterium tuberculosis
H37Rv at a concentration of 6.25 µg/ml using Rifampicin as a standard drug,
which have been tested by Tuberculosis Antimicrobial Acquisition
Co-ordinating Facility (TAACF), Alabama U.S.A.
[2] All the compounds have been evaluated for their antibacterial activity  towards
Gram positive and Gram negative bacterial strains and antifungal activity
towards Aspergillus niger at a concentration 40 µg/ml. The biological
activities of the  synthesized compounds have been compared with
standard drugs.




The progress of drug design is extensively driven by the instincts, intuition
and experience of pharmaceutical research scientists. It is often instructive to attempt
to ‘capture’ these experiences by analyzing the historical record that is successful
drug design projects to past. From this analysis the interference draw to play an
important role in shaping our on current and future projects. Towards this region,
we would like to analyze the structures of a large number of drugs.
The focus of drug design has switched from structure oriented to target
oriented research, e.g. development of the antiulcer agent cimetidine. Histamine
was the lead compound for the project and various strategies were used to find an
analog that would prevent it fitting its receptor. Once an antagonist was developed,
a theory was proposed on how it might interact with the histamine receptor at a
molecular level. Further analogs were then synthesized to test theory and the theory
was continuously modified as required.
        In the nineteenth century, chemistry developed as a science, both in terms of
experimental procedures and scientific theory. Scientist isolated and purified single
compounds from natural extracts. Method of organic synthesis were developed that
helped chemists altering structures in a predictable way.
A prerequisite for the design of safe drugs is knowledge about the various
metabolic reactions that xenobiotics and endogenous compounds undergo in the
organism. Because pharmacological activity depends on molecular structure, the
medicinal chemist is restricted in the choice of functional groups for the design of
new drugs. Often he finds or she encounters a situation where a structure has
adequate pharmacologic activity but has an inadequate pharmacokinetic profile
(i.e.,  absorption, distribution, metabolism and excretion). This is because
pharmacology and pharmacokinetic departments in the pharmaceutical industry often
do not collaborate at the early stage of drug development. It is only later, when the
Design and Synthesis ...
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new compound is tested in animals or in humans, that pharmacokinetic disadvantages
become obvious.
Modern drug discovery starts with the identification of a pharmacologic
target that is hypothetically the primary cause of disease. Potential targets include
host cell genes, receptors, signaling systems, organelles and biochemicals such as
enzymes. Additionally, an element of a disease modifying process, such as an
inflammatory mediator, may be a target. Biological processes required for
propagation of infectious agents have also proven to be therapeutically useful
targets; examples include protease and reverse transcriptase of the human immuno
deficiency virus(HIV). Common to all targets selected as therapeutic opportunities
is the hypothesis that some type of pathogenetic linkage exists to the disease-
causing process, rather than to specific signs, symptoms, or effects.
Heterocyclic compounds have great applicability in pharmaceutics because
they have specific chemical reactivity and provides false synthons in biosynthetic
process or block the normal functioning of biological receptors. The inhibition of
amide resonance resulting into more susceptibility of β-lactam to nucleophile is
considered at least in part responsible for antibacterial property, apparently by
acetylating transpeptidase and thus inhibiting bacterial cell wall biosynthesis.
Most of the alkaloids which are nitrogenous bases occurring in plants and
many antibiotics including penicillin and streptomycin have also heterocyclic ring
system. Many natural pigments such as indigo, haemoglobin and anthocyanin are
heterocycles. Most of the sugars are their derivatives including Vitamin C for
instance, exist largely in the form of five membered. Vitamin B6 (Pyridoxine) is a
derivative of pyrimidine essential in aminoacid metabolism.
Important drugs, poisons and medicines (both natural and synthetic) such as
sulphathiazole, pyrenthrin, rotenmone, strychnine, reserpine, certain of the
antihistamines, the ergot alkaloids caffeine, cocaine, barbiturates, etc. are




The ultimate product of a successful drug design effort. Our goal for this is
to begin to deconvolute this information in order to apply it to design of new drugs.
Taking in view of the applicability of heterocyclic compounds, we have
undertaken the preparation of heterocycles bearing pyrazole nucleus. The placement
of a wide variety of substituents of these nuclei have been designed in order to
evaluate the synthesized products for their pharmacological profile against several
strains of bacteria and fungi.
AIMS AND OBJECTIVES :
“ To generate several derivatives like chalcones, pyrazolines, cyanopyridines,
cyanopyridones, cyclohexenones, indazoles, aminopyrimidines, thiazolidinones,
thiopyrimidines, oxopyrimidenes and imidazolines bearing pyrazole moiety.
“ To characterize these products for structure elucidation using spectroscopic
technique like IR, PMR and Mass spectral studies.
“ Purity of all compounds have been checked by thin layer chromatography.
“ To evaluate these new product for better drug potential against different
strain of bacteria, fungi and for antitubercular activity.
STUDIES ON
1,3-DIARYL PYRAZOLES




Pyrazoles are well known five membered heterocyclic compounds and several
procedure for there synthesis have been extensively studied. Such studies have been
stimulated by various promising applications, especially in the case of N-substituted
pyrazole derivatives. In fact,  certain N-substituted pyrazoles are used as
pharmaceuticals e.g. analgesic, anti-inflammatory, antipyretic, agrochemicals
whereas some other is being studied for their medicinal interest.
The knowledge of such applications has pointed out that N-substituted
pyrazoles are important target to be prepared to our interest on synthesis and
molecular structure determination of some types of pyrazoles.
The pyrazole ring system (I) consists of a doubly unsaturated five membered
ring containing two adjacent nitrogen atoms. Knorr1,2 first synthesized a compound
containing this  system in  1883 by a  react ion of  e thylacetoacetate  with
phenylhydrazine, which yield 1-phenyl-3-methyl-5-pyrazolone (II).
Knorr3 introduced the name pyrazole for these compounds to donate that the
nucleus was derived from pyrrole by replacement of carbon by nitrogen; since many
drugs and dyes contain the pyrazole nucleus, the class has been widely studied and
the field continuous to be active today even though antipyrine and related medicine















Various methods for the preparation of pyrazoles have been cited in literature.
1. The reaction of hydrazine or its derivatives such as alkyl or aryl hydrazines,
semicarbazine or aminoguanidine with 1,3-dicarbonyl compounds.
2. The reaction of hydrazines with α,β-unsaturated carbonyl compounds.
3. The reaction of aliphatic diazo compounds such as diazomethane or
diazoester with acetylene or olefins.
THERAPEUTIC IMPORTANCE
Much research has been carried out with the aim to finding therapeutic values
of pyrazole moiety since their discovery. A large number of substituted pyrazole
derivatives are prepared and tested for variety of biological activities like.
1.   Antiinflammatory4-5
2.   Insecticidal6
3.   p-38 Kinase inhibitors7-10
4.   Antiepileptic11
5.   Nematicidal12
6.   Antitumor13
7.   Anticancer14
8.   Antiviral15
9.   Herbicidal16-19
10. AntiHIV20
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Somega Shinzo and co-workers22 have synthesized pyrazole derivatives and reported
their herbicidal activity. Geheing Reinhald et al.23 have synthesized 5-amino-4-cyano-
1-aryl-pyrazoles and shown them as plant growth inhibitors. Nakamura Katsyga
and co-worker24,25 have prepared 1,5-diphenyl pyrazoles as Cox-2-inhibitors (III).
Pier Giovanni Baraldi et al.26 have synthesized pyrazole derivatives as
antileukemic agents. Thomas Alan Crowell et al.27 prepared new pyrazoles as
selective α-adrenergic agonists. Kevin M. Moore et al.28 prepared pyrazoles as human
dopamine-D4-receptors while Bernard Banks et al.29 have synthesized pyrazole
derivatives (IV) and tested for their antiparasitic activity.
Laborde Edgardo et al.30 have found that pyrazoles possess glycine
transporter-2-inhibitor activity. Andrew Thurkaub et al.31 have synthesized high
affinity C5a receptor modulator pyrazoles. Nagaaki Sato et al.32 have prepared
pyrazoles as neuropeptide T5 receptor antagonist. G. M. Hi Yamanonch33 has
prepared pyrazoles as glycine transporter protein inhibitors.
Feid-Allah Hassan34 have prepared pyrazoles and reported their antidiabetic
and antibacterial activity. Ejima Akio et al.35 have synthesized pyrazole derivatives
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Jacques Dumas and co-workers36 have synthesized pyrazole derivatives as
rafkinase and angiogenesis inhibitor agents. David L. S. et al.37 have reported
pyrazoles as activators of the nitrile oxide receptor and soluble guanglate cyclase
agent. T Van Herk et al.38 have demonstrate pyrazoles as nicotinic acid receptor
(VI). Barber Christopher et al.39 have synthesized pyrazole derivatives as
phosphodiesterase inhibitors.
Recently, Atkinson R. N. et al.40 have synthesized pyrazoles as sodium channel
Blocker (VII). Murakanii Hiroshi et al.41 have synthesized pyrazoles as antifouling
agent. Gellibert Francoise et al.42 have prepared pyrazole derivatives as TGF-13
inhibitors.
Grazid Mamalo et al.43 have newly synthesized pyrazole derivatives tested
for antimicrobial activity. R. Y. Huang and co-workers44 have prepared some 1,2,4-
triaryl-4-alkyl-pyrazoles as estrogen receptor. C. Vittoria and co-workers45 have
prepared some pyrazoles as adenosine receptor antagonists.
Schindler Ursula et al.46 synthesized new pyrazole derivatives (VIII) as
cardiovascular agents. Havaldar Freddy et al.47 synthesized 4,5-dihydro 3-phenyl-
1H-pyrazole and reported their biological activity. Carbau Romuald and co-workers48
have prepared pyrazole derivatives (IX) useful as reverse transcriptase inhibitors
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Nishimura Tsoshihiro et al.49 have synthesized pyrazoles as inhibitors of human
SGLT2 (sodium dependent glucose transporter-2). From Recent literature it has
found that pyrazole derivatives possesses a number of biological activities, such as
fungicidal,50,51 herbicidal,52-55 cardiovascular,56 antiinflammatory,57-59 Cox-II inhibitor,60
antimicrobial,61 anticancer,62-64 protein kinase inhibitor,65-68 antibacterial,69,70 antiviral,71
antiparasitic,72 HIV reverse transcriptase inhibitor73,74 and 5-H T2O receptors.75-77
Ji Yang et al.78 have documented 3-(4-phenoxyphenyl)pyrazole derivatives
(X) for their Sodium Channel Blockers. Ruoxi Lan et al.79 have prepared pyrazole
derivatives as Cannabinoid receptor antagonist.(XI)
Akihiko Tanitame et al.80 have synthesized pyrazole derivatives (XII) as
ant ibacter ia l  act ivi ty  and select ive inhibi tory act ivi ty  against  bacter ia l
topoisomerases. Gregory R. Bebernitz et al.81 have described 1,3-diaryl-[1H]-
pyrazole-4-acetamide as antidiabetic agents (XIII). Franco chimenti, Adriana Bolasco
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Abdel-rahman farghaly and hussein el-kashef et al.83 have prepared pyrazole
derivatives as antibacterial and antifungal activities. Pierluigi caboni  et al.84 have
reported phenylpyrazole insecticide photochemistry, metabolism and gabaergic
action(XIV). Craig W. Lindsley et al.85 have discovered positive allosteric Modula-
tors for the Metabotropic Glutamate Receptor from a series of N-(1,3-diphenyl-
1H-pyrazol-5-yl)benzamides that potentiate receptor function in vivo(XV).
Adrian l. Gill and Martyn Frederickson et al.86 have identified pyrazole as a
novel p38α MAP kinase inhibitors(XVI). Jeffrey roppe et al.87 have discovered novel
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Literature survey reveals that the compounds bearing pyrazole moiety possess
potential drug activity. Looking to the diversified biological activity, it appeared of
interest to synthesize some chalcones, pyrazolines, cyanopyridines, cyanopyridones,
cyclohexenones, indazoles, aminopyrimidines, thiazolidinones, pyrimidinones,
imidazolinones and bearing pyrazole moiety, in order to achieving compounds having
better therapeutic importance. These studies are described in following parts.
STUDIES ON 1,3-DIARYL PYRAZOLES :
PART - I : STUDIES ON CHALCONES
PART - II : STUDIES ON PYRAZOLINES
PART - III : STUDIES ON CYANOPYRIDINES
PART - IV : STUDIES ON CYANOPYRIDONES
PART - V : STUDIES ON INDAZOLES
PART - VI : STUDIES ON AMINOPYRIMIDINES
PART - VII : STUDIES ON THIAZOLIDINONES
PART - VIII : STUDIES ON PYRIMIDINONES
PART - IX : STUDIES ON IMIDAZOLINONES
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The chemistry of chalcones have generated intensive scientific studies
throughout the world, specially interesting for there their biological and industrial
applications. Chalcones are coloured compounds because of the presence of the
chromophore and auxochromes. They are known as benzalacetophenones or
benzylidene acetophenones. Kostanecki and Tambor1 gave the name Chalcone.
Chalcones are characterized by their possession of a structure in which two
aromatic rings A and B are linked by an aliphatic three carbon chain.
(I)
The alternative names given to chalcones are phenyl styryl ketones,
beanzalacetophenone, β-phenyl acrylphenone, γ-oxo-α,γ-diphenyl-α-propylene and
α-phenyl-β-benzoethylene.
SYNTHETIC ASPECT :
A considerable variety of methods are available in literature for the synthesis
of chalcones.  The most convenient  method is  the one,  that  involves the
Claisen-Schimidt condensation of equimolar quantities of an aryl methyl ketones
with arylaldehyde in presence of alcoholic alkali.2
Several condensing agents used are alkali of different strength3,4 hydrochloric
acid,5,6 phosphorous oxychloride,7 piperidine,8 anhydrous aluminium chloride,9 boron
trifluoride,10 aqueous solution of borax,11 amino acids,12 perchloric acid13 etc.
O
A B




Chalcone formation proceeds through Aldol type condensation and the process
is catalyzed by the presence of alkali.14 Following are the steps of the reaction
mechanism.
The intermediate Aldol type products formed readily undergoes dehydration
even under mild condition, particularly when R and R’ are aryl groups.
REACTIVITY OF CHALCONES :
The chalcones have been found to be useful for the synthesis of variety of
heterocyclic compounds are as under.
(a) Chalcones with monoethanolamine in ethanol gives 1,4-oxazipines.15
(b) Chalcones with 2-amino thiophenol  in acet ic  acid produces 1,5-
thiazepines.16
(c) Chalcones on reaction with semicarbazide hydrochloride in ethanol affords
1-carboxamide pyrazolines.17
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(e) Oxirane19 can be prepared by the reaction of chalcone with H2O2 in basic
media.
(f) Cyanopyridone20 derivatives can be prepared by the condensation of
chalcone with ethyl cyanoacetate.
(g) Chalcones on reaction with barbituric acid gave barbitone21 derivatives.
(h) Chalcone gives imine derivatives with amine in presence of sulfuric acid as
catalyst.22
(i) Pyrazolines23 and its derivatives can be prepared by the condensation of
chalcones with hydrazine hydrate and acetic acid.
(j) Chalcones on condensation with malononitrile and ammonium acetate
yields 2-amino-3-cyano pyridines.24
( k) Isoxazoles 25 can  be  prepared by the  t rea tment  of  chalcones  wi th
hydroxylamine hydrochloride and sodium acetate.
(l) Chalcones on condensation with malononitrile in pyridine forms 2-amino-
3-cyano-pyrans.26
(m) Chalcones  on t rea tment  wi th  urea  in  presence  of  a lkal i  a ffords  2-
oxopyrimidines.27
(n) Chalcones on reaction with thiourea in presence of alkali/acid yields
2-thienopyrimidines.28
(o) Chalcones on treatment with guanidine hydrochloride in presence of
alkali affords 2-amino pyrimidines.29
(p) Chalcones react with P2S5 yielded 2-isothiazolidines.
30
(q) Chalcones react with sodium nitrile in presence of glacial acetic acid in
ethanol produces 2-1H-pyrimidines.31




Chalcones are potential biocides, some naturally occurring antibiotics and
amino chalcones probably own their biological activity due to the presence of














Recently Ni Liming et al.50 have synthesized chalcones and screened for their
antiinflammatory and cardiovascular activity. Kumar Srinivas et al.51 have synthesized
chalcones as a antitumor agent. Ko Horng-Huey et al.52 have prepared chalcones as
antiinflammatory agent. Nakahara Kazuhiko et al.53 have synthesized chalcones as
carcinogen inhibitors. Antitubercular agents of chalcone derivatives have been
prepared by Lin Yuh-Meei et al.54
Ezico et  al . 55 have demonstrated that  chalcone possess a valuable
antiproliferation activity both on sensitive cancereous cell and on cell which are
resistant to common chemotherapeutic drugs. Some of the chalcones have been
patented for their use for treatment of glucoma56 and showed antifungal57,58 aldose
reductase inhibitors,59 anticancer60 and antimicrobial61,62 activities.
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Das B. P. et al.63 have found that chalcones possesses larvicidal properties.
Kim Min-Young et al.64 have synthesized chalcones and tested for their matrix
metalloproteinase inhibitor activity. Satyanarayana M. et al.65 have synthesized
chalcone derivatives as antihyperglycemic activity(II).
Moreover, synthesis and antibacterial activity of substituted chalcone
derivatives have been reported by Modi et al.66 and Attia A.67 V. Mudalir et al.68
have prepared phenoxychalcones and observed their insecticidal activity,  Kammei
et al.69 have synthesized chalone derivatives having antitumor activity. De Vincenzo
et al.70 and Han et al.71 have reported chalcone derivatives for their antiinflammatory
activity.
Aldose reductase inhibitor activity of chalcone derivatives have been reported
by Okuyama et al.72 They are also associated with antitumor and antifungal activity
as reported by A. Tsotitns and coworkers.73 Antifeedant activity of chalcones have
been observed by Sharma and Sreenivasulu.74
Liu Mei et al.75 have prepared antimalarial chalcones. Opletalova Veronika
et al.76 have synthesized chalcones and screened as cardiovascular agents. Moreover,
it has been found that chalcone derivatives possesses nitric oxide inhibitor,77,78
anti HIV79,80 and antiproliferative81,82 activities. Meng C. Q. et al.83 discovered some
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Moreover, Khatib S. et al.84 synthesized some novel chalcones as potent
tyrosinase inhibitors(IV). Ko H. H. et al.85 have prepared some new chalcones for
potent inhibition of platelet aggregation. Ziegler H. L. et al.86 reported some
chalcones as antiparasitic. Go M. L. et al.87 have described the synthesis and
biological activities of chalcones as antiplasmodial. Xue C. X. et al.88 synthesized
chalcones as antimalarial agents. Fu Y. et al.89 have synthesized Licochalcone-A.
Furthermore, Alcaraz M. J. et al.90 have described the role of nuclear
factor-kappaB and heme oxygenase-1 in the action of an anti-inflammatory chalcone
derivative in RAW 264.7 cells. Nerya O. et al.91 have prepared some new chalcones
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Sabzevari O. et al.92 have constructed some new chalcone derivatives as
Molecular cytotoxic mechanisms of anticancer hydroxychalcones(V).
Recently, Ban H. S. et al.93 have synthesized some novel chalcones as inhibition
of lipopolysaccharide-induced expression of inducible nitric oxide synthase and tumor
necrosis factor-alpha by 2'-hydroxychalcone derivatives in RAW 264.7 cells. Hollosy
F. et al.94 have prepared some new chalcones as Plant-derived protein tyrosine kinase
inhibitors as anticancer agents.
These valid observation led us to explore chalcone chemistry by synthesizing
several derivatives like pyrazolines, cyanopyridones, cyclohexenones, indazoles and
aminopyrimidines bearing different heterocyclic ring systems for medicinal value,
in order to achieving better therapeutic agents, this study described as under.
SECTION-I    : SYNTHESIS AND BIOLOGICAL EVALUATION OF 1-
A RY L - 3 - { 1 ' , N - P H E N Y L - 3 ' - [ p - ( M E T H Y LT H I O )
PHENYL]-PYRAZOL-4'-YL}-2-PROPENE-1-ONES




SYNTHESIS AND BIOLOGICAL EVALUATION OF 1-ARYL-3-{1',N-
PHENYL-3'-[p-(METHYLTHIO)PHENYL]-PYRAZOL-4'-YL}-2-PROPENE-
1-ONES
With the biodynamic activities of chalcones and it is a good synthon for
various heterocyclic rings, the interest has been focussed on the synthesis of new
chalcones. With a view to obtained compounds having better therapeutic activity,
we have synthesized 1-aryl-3-{1',N-phenyl-3'-[p-(methylthio)phenyl]-pyrazol-4'-yl}-
2-propene-1-ones by the condensation of 1,N-phenyl-3-[p-(methylthio)phenyl]-4-
formyl pyrazole with various aromatic ketones in presence of catalyst of alkali.
The constitution of the synthesized products have been characterized by using
elemental analyses, infrared and 1H-nuclear magnetic resonance spectroscopy and
further supported by mass spectroscopy.
All the products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains
and antifungal activity towards Aspergillus niger at a concentration of 40 µg/ml.
The biological activities of the synthesized compounds were compared with standard
drugs. The details have been cited in Part-I, Section-I (D).
Moreover, some selected compounds have been evaluated for their in vitro
biological assay towards a strain of Mycobacterium tuberculosis H37Rv at a
concentration of 6.25 µg/ml using Rifampin as a standard drug which have been
tested at Tuberculosis Antimicrobial Acquisition Co-ordinating Facility (TAACF),
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Alkane C-H str. (asym.) 2966 2975-2950 95
-CH3 C-H str. (sym.) 2877 2880-2860  ,,
C-H i.p.def. (asym.) 1436 1470-1435  ,,
C-H o.o.p. def. (sym.) 1384 1390-1370  ,,
Aromatic C-H  str. 3070 3090-3030 96
C=C str. 1502 1540-1480  ,,
C-H i.p. (def.) 1093 1125-1090  ,,
C-H o.o.p. (def) 1031 1070-1000  ,,
Pyrazole C=N str. 1596 1610-1590 96
moiety C-N str. 1215 1230-1020  ,,
α,β-unsaturated C=O str. 1660 1700-1640 95
ketone CH=CH str. 1502 1644-1618  ,,
C-H wag. 979 980-965  ,,
Halogen C-Cl str. 686 600-800  ,,
Type        Ref.
        Reported
Frequency in cm-1 Vibration
Mode
IR SPECTRAL STUDIES OF 1-(p-CHLOROPHENYL)-3-{1',N-PHENYL-
3'-[p-(METHYLTHIO)PHENYL]-PYRAZOL-4'-YL}-2-PROPENE-1-ONE
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1 2.5 3H singlet Ar-SCH3     -
2 3.8 3H singlet Ar-OCH3     -
3 6.93-6.97 2H doublet Ar-Hj,j’ Jji=9.6
4 7.31-7.37 3H multiplet Ar-H(a,c,e)     -
5 7.34-7.46 1H doublet -CHk Jkl=15.9
6 7.46-7.57 2H triplet Ar-H(b,d)     -
7 7.62-7.66 2H doublet Ar-Hg,g’ Jgf=8.4
8 7.77-7.80 2H doublet -CH i,i’ Jij=9
9 7.80-7.83 1H doublet Ar-Hl lk=15.9
10 7.95-8.0 2H doublet Ar-Hf,f’ Jfg=8.7




    (δppm)
 Relative No.
  of protons
Multiplicity Inference    J Value






















NMR SPECTRAL STUDIES OF 1-(p-METHOXYPHENYL)-3-{1',N-PHENYL
-3'-[p-(METHYLTHIO)PHENYL]-PYRAZOL-4'-YL}-2-PROPENE-1-ONE
Instrumental Standard : TMS; Solvent: CDCl3 ; Instrument : BRUKER Spectrometer (300MHz)












































































































Gram positive bacteria : Bacillus coccous
Bacillus subtillis
Gram negative bacteria : Proteus Vulgaris
Escherichia Coli
Fungi : Aspergillus niger
Concentration : 40µg/ml
Solvent : Dimethyl formamide
Standard drugs : Amoxicillin, Ampicillin, Benzyl penicillin,
Norfloxacin, Greseofulvin
The antimicrobial activity was compared with standard drug viz Amoxicillin,
Ampicillin, Benzyl penicillin, Norfloxacin and antifungal activity was compared with
viz Greseofulvin. The inhibition zones measured in mm.
ANTITUBERCULAR ACTIVITY
The antitubercular evaluation of the compounds was carried out at
Tuberculosis Antimicrobial Acquisition Co-ordinating Facility (TAACF) U.S.A.
Method : BACTEC 460 Radiometric system.
Bacteria : Mycobacterium Tuberculosis H37Rv
Concentration : 6.25 µg/ml.
Standard drug : Rifampin.
MICROBIOLOGICAL EVALUATION




SYNTHESIS AND BIOLOGICAL EVALUATION OF 1-ARYL-3-{1',N-
PHENYL-3'-[p-(METHYLTHIO)PHENYL]-PYRAZOL-4'-YL}-2-PROPENE-
1-ONES
[A] Synthesis  of  N-Phenylamine-α-methyl-α-[p-(methylthio)phenyl]-
azomethine
A mixture of phenylhydrazine (1.08 gm, 0.01 mol) and 1-[4-(methylsulfanyl)
phenyl]ethanone (1.66 gm, 0.01 mol) in absolute ethanol was refluxed on waterbath
for 4 hrs. in presence of 1ml glacial acetic acid. Product obtained after cooling was
crystallized from absolute ethanol. Yield 78%; m.p. 69oC; Anal. Calcd. for
C15H16N2S; Required: C, 70.27; H,6.29; N,10.93 %; Found: C, 70.24; H, 6.25;
N,10.89 %.
[B] Synthesis of 1,N-Phenyl-3-[p-(methylthio)phenyl]-4-formyl pyrazole
N-Phenylamine-α-methyl-α-[p-(methylthio)phenyl]-azomethine(2.56 gm,
0.004 mol) was added into a Vilsmeier-Haack reagent (prepared by dropwise addition
of 1.2 ml POCl3 in ice cooled 10 ml DMF) and refluxed for 6 hrs. The reaction
mixture was poured on to crushed ice followed by neutralization using sodium
bicarbonate. Crude product was isolated and crystallized from methanol. Yield, 83%;
m.p. 124oC; Anal. Calcd. for C17H14N2OS; Required: C,69.36; H,4.79; N,9.52 %
Found : C,69.31 ; H,4.75; N,9.49 %.
[C] Synthesis of 1-(p-Anisyl)-3-{1'-N-phenyl-3'-[p-(methylthio)phenyl]-
pyrazol-4'-yl}-2-propene-1-one
To a solution of 1,N-phenyl-3-[p-(methylthio)phenyl]-4-formyl-pyrazole
(2.94 gm, 0.01 mol), p-methoxy-acetophenone (1.5 gm, 0.01 mol) in ethanol
(25 ml) and 40% NaOH added till the solution become basic. The reaction mixture
was stirred for 24 hrs. The contents were poured on to crushed ice. Upon
neutralization the solid was separated and crystallized from ethanol. Yield,76%;
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m.p.210oC. Anal. Calcd. for C26H22N2O2S; Required : C,73.21; H, 5.20 ; N, 6.57%
; Found : C, 73.18; H, 5.16; N, 6.52%.
Similarly other 1-aryl-3-{1',N-phenyl-3'-[p-(methylthio)phenyl]-pyrazol-
4 '-yl}-2-propene-1-ones were prepared. The physical data are recorded in Table
No. 1.
[D] Antimicrobial and antitubercular activity of 1-Ary-3-{1',N-phenyl-3'-
[p-(methylthio)phenyl]-pyrazol-4'-yl}-2-propene-1-ones
All the compounds have been evaluated for antimicrobial and antitubercular
activity as described under.
(a) Antimicrobial activity97
It was carried out buy cup-plate diffusion method which has been described
as under.
(I) Antibacterial activity
The purified products were screened for their antimicrobial activity. The
nutrient agar bath prepared by the usual method, was inoculated aseptically with
0.5 ml of 24 hrs. old subcultures of B. coccous, B. subtillis, E. Coli, P. vulgaris in
separate conical flasks at 40-50oC and mixed well by gentle shaking. About 25ml
content of the flask were poured and evenly spreaded in a petridish (13cm in
diameter) and allowed to set for 2 hrs. The cups (10 mm in diameter) were formed
by the help of borer in agar medium and filled with 0.04ml (40µg) solution of sample
in DMF.
The plates were incubated at 37oC for 24 hrs. and the control was also
maintained with 0.04 mole of DMF in a similar manner and the zones of inhibition
of bacterial growth were measured in millimeter and are recorded in Graphical Chart
No.1.




A. niger was employed for testing antifungal activity using cup-plate method.
The culture was maintained on subouraud’s agar slants. Sterilized sabouraud’s agar
medium was inoculated with 72 hrs. old 0.5 ml suspension of fungal spores in a
separate flask.
About 25 ml of inoculated medium was evenly spreaded in a petridish and
allowed to set for two hrs. The plates were incubated at 30oC for 48 hrs. After the
completion of incubation period, the zone of inhibition of growth in the form of
diameter in mm was measured. Along the test solution in each petridish one cup
was filled with solvent which act as control. The zones of inhibition are recorded in
Graphical Chart No. 1.
(C)Antitubercular activity
The antitubercular evaluation of the compounds was carried out at
Tuberculosis Antimicrobial Acquisition and Co-ordination Facility (TAACF), USA.
Primary screening of the compounds for the antitubercular activity have been
conducted at 6.25 µg/ml towards Mycobacterium tuberculosis H37Rv in BACTEC
12B using the BACTEC 460 radiometric system. The compounds demonstrating
atleast>90% inhibition in the primary screening has been tested at lower
concentration towards Mycobacterium tuberculosis H37Rv to determine the actual
minimum inhibitory concentration (MIC) in the BACTEC-460.
The antitubercular data have been compared with standard drug Rifampin at
6.25 µg/ml concentration and it showed 98% inhibition. The primary screening
method is described as under.
Antitubercular activity was determined using the BACTEC 460 system as
modif ied  be low.  Stock so lu t ions  as  tes t  compounds  were  prepared  in
dimethylsulfoxide (DMSO) at 1 µg/ml and sterilized by passage through 0.22 mm
PFTE filters (Millex-FG, Millipore, Bedford MA). Fifty microliters was added to
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4ml radiometric 7H12 broth (BACTEC 12B; Becton Dickinson Diagnostic
Instrument System, Sparks, MD) to achieve a final concentration of 6.25 µg/ml.
Controls received 50 ml DMSO. Rifampin was solubilized and diluted in DMSO
And added to BACTEC-12 broth to achieve a range of concentration for
determination of minimum inhibitory (MIC, lowest concentration inhibiting 99% of
the inoculum).
M. Tuberculosis H37Rv (ATCC 27294; American type culture collection,
Rockville, MD) was culture at 37 oC on a rotary shaker in middlebrook 7H9 broth
(Difco Laboratories, Detroiet, MI) supplemented with 0.2 v/v glycerol and 0.05%
v/v Tween 80 until the culture turbidity achieved an optical density of 0.45-0.55 at
550nm. Bacteria were then pelleted by centrifugation, washed twice and resuspended
in one fifth the original volume in dulbecco’s phosphate buffered saline (PBS, Irvine
Scientific Santa, Nalgene, Rochester, NY) and aliquots were frozen at 80 oC.
Cultures were showed and an appropriate dilution performed such that a BACTEC-
12B vial inoculated with a 0.1 ml would reach a growth index (GI) of 999 in 5 days.
One tenth of diluted inoculum was used to inoculate 4 ml fresh BACTEC-
12B broth containing the compounds. An additional control vial was included which
received a further 1:100 diluted inoculam (as well as 50 ml DMSO) use an calculating
the MIC of Rifampin, respectively by establishing procedures.
Cultures were incubated in 37 oC and the GI determined daily until control
cultures achieved a GI og 999. Assays were usually completed in 5-8days. Percent
inhibition was defined as-1- (GI of test sample/GI of control) x 100. Minimum
inhibitory concentration of compound effecting a reduction in daily change in GI,
which was less than that, observed with a 1:100 diluted control culture one day the
letter reached a GI of at least 30. The percentage of inhibition data of compounds
are recorded in Table No. 1
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1a 182276 PT-1 C6H5- Alamar H37Rv >6.25 00
1b 182277 PT-2 4-Cl-C6H4- Alamar H37Rv >6.25 00
1c 182278 PT-3 4-Br-C6H4- Alamar H37Rv >6.25 37
1d 182279 PT-4 4-CH3-C6H4- Alamar H37Rv >6.25 00
1e 182280 PT-5 4-OCH3-C6H4- Alamar H37Rv >6.25 00
1f 182281 PT-6 4-SCH3-C6H4- Alamar H37Rv >6.25 12
1g 182282 PT-7 4-OH-C6H4- Alamar H37Rv >6.25 00
1h 182283 PT-8 2-OH-C6H4- Alamar H37Rv >6.25 00
1i 182284 PT-9 3,5-(Br)2-4-OH-C6H2- Alamar H37Rv >6.25 46
1j 182285 PT-10 4-NO2-C6H4- Alamar H37Rv >6.25 16
1k 182286 PT-11 3-NO2-C6H4- Alamar H37Rv >6.25 10
1l 182287 PT-12 4-NH2-C6H4- Alamar H37Rv >6.25 00




   ID
 Corp
   ID
R Assay    Mtb
  Strain
     %
Inhibi.
   MIC
 µg/ml
TABLE  NO. 1
TAACF, Southern Research Institute
Primary Assay Summary Report








ANTITUBERCULAR ACTIVITY OF 1-ARYL-3-{1' ,N-PHENYL-3'-[p-
(METHYLTHIO)PHENYL]-PYRAZOL-4'-YL}-2-PROPENE-1-ONES
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    PART - II
STUDIES ON
PYRAZOLYL PYRAZOLINES




Amongst nitrogen containing five membered heterocycles, pyrazolines have
proved to be the most useful frame work for biological activities. Pyrazolines have
attracted attention of medicinal chemist for both with regard to heterocyclic
chemistry and the pharmacological activities associated with them. In 1967 Jacobe,
reviewed the chemistry of pyrazolines, which have been studied extensively for their
biodynamic behavior
1
 and industrial applications.
2
SYNTHETIC ASPECT :
Different methods for the preparation of 2-pyrazoline derivatives documented
in literature are as follows.
1. 2-Pyrazolines can be synthesized by the cycloaddition of diazomethane to
substituted chalcone.
3
2. Dipolar cycloaddition of nitrilimines of dimethyl fumarate, fumaronitrile and
the N-aryl maleimides yielded the corresponding pyrazolines.
4
3. Epoxidation of chalcones with epoxy ketones on reaction with hydrazine
hydrate and phenyl hydrazine to give pyrazolines.
5
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5. 2-Pyrazolines can also be prepared by the condensation of chalcone dibromide
with hydrazine.
7
Furthermore, B. Gyassi et al.
8
 have investigated the one pot synthesis of





 have also described the microwave assisted synthesis of 2-pyrazolines.
MECHANISM :
The following mechanism seems to be operable for pyrazoline by the
condensation of chalcones with hydrazine hydrate.
11
Nucleophilic attack by hydrazine at the b-carbon of the a,b -unsaturated
carbonyl system forms species (II), in which the -ve charge is mainly accommodated
by the electronegative oxygen atom.
Proton transfer from the nitrogen to -ve oxygen produces an intermediate
enol which simultaneously ketonises to ketoamine (III). Another intramolecular
nucleophilic attack by the primary amino group of ketoamine on its carbonyl carbon
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amine (IV). The later with a hydroxy group and amino group on the same carbon
lose water molecule to yield the pyrazolines.
THERAPEUTIC IMPORTANCE
From the literature survey, it was revealed that 2-pyrazolines are better
therapeutic agents. Some of the activities are mentioned below.
1.   Antiallergic
12
2.   Anticonvulsant
13,14
3.   Antidiabetic
15
4.   Antiimplantation
16
5.   Antiinflammatory
17
6.   Antitumor
18
7.   Antineoplastic
19
8.   Antimicrobial
20


















Shivnanda M. K. and co-workers
32
 have prepared pyrazolines and reported
their antibacterial activity. E. Palska et al.
33  have prepared 3,5-diphenyl-2-pyrazolines
(I) and cited their antidepressant activity.










Moreover, F. Manna and coworkers
34
 have described 1-acetyl-5-(2'-
bromophenyl)-4,5-dihydro-3-(2'-hydroxyphenyl)-1H-pyrazolines (II) and its
derivatives which acts as potent antiinflammatory, analgesic and antipyretic agents.
(II)
S. S. Sonarc et al.
35
 have synthesized 3-(2-acetoxy-4-methoxyphenyl)-5-
(substituted-phenyl)-pyrazolines (III) and tested their antimicrobial activity. V. V.
Fernandes et al.
36
 have also synthesized some new pyrazolines as an antimicrobial
agent.











R1 = H,Cl, Br, Me, MeO
R2 =H, Cl
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Udupi R. H. and Bhatt A. R.
37
 have reported the synthesis and biological
activity of Mannich bases of certain 1,2-pyrazolines. Nugent Richard
38
 investigated
pyrazolines bis phosphonate ester as novel antiinflammatory and antiarthritic agent.
Fuche Rainer et al.
39
 have prepared some new 1H-pyrazoline (IV) derivatives and
reported them as pesticides.
Furthermore, Tsuboi et al.
40
 have synthesized some new phenylcarbonyl
pyrazolines (V) as an insecticides and at 40% concentration shows 100% mortality
of spodopetra litura larve after seven drops.
G. N. Mishirika et al.
41
 have also prepared 2-pyrazolines of salicylic acid
(VI) possessing antimicrobial properties.
Tuntawy Atif and coworkers
42
 have patented 3-methyl-4'-(substituted
phenylazo)-pyrazol-5-ones as antibacterial agent.
Almstead J. et al.
43
 have prepared pyrazolines as vascularization agent. Guniz
Kucukguzel et al.
44
 have synthesized pyrazolines as a antimicrobial and anticonvulsant
agents. Gulhan T. Z. and coworkers
45
 have prepared pyrazolines as a hypotensive
agent. Shalabh Sharma et al.
46
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Ashok Kumar et al.
47
 have synthesized pyrazolines as anticonvulsant agents
(VIII). Maurer Fritz et al.
48
 have synthesized pyrazoles and screened for their
pesticidal activity.
Moreover, T. M. Stivenen et al.
49
 have also investigated N-substituted
pyrazoline type insecticides. Tanka Katsohori
50
 have patented pyrazoline derivatives
as herbicides and Johannes et al.
51
 have reported as insecticides. Moritaz Z. and
Hadol
52
 to investigated a semi imperial molecular orbital study on the reaction of
aminopyrazolinyl azodye with singlet molecular oxygen.
B. Shivarama Holla et al.
53,54
 have synthesized pyrazolines as antibacterial
agent.  Hiremath S. P. et  al .
55
 have synthesized pyrazolines as analgesic,
antiinflammatory and antimicrobial agent. Malhotra V. et al.
56
 have synthesized new
pyrazolines as a cardiovascular agent (IX).
Moreover, Ahn J. H. et al.
57
 have described the synthesis and DP-IV inhibition
of cyano-pyrazoline derivatives as potent antidiabetic agents. Jeong T. S. et al.
58
have synthesized some novel 3,5-diaryl pyrazolines as human acyl-CoA:cholesterol
acyltransferase inhibitors. Nasr M. N. et al.
59
 have reported the synthesis of Novel
3,3a,4,5,6,7-hexahydroindazole and arylthiazolylpyrazoline derivatives as
antiinflammatory agents. Berghot M. A. et al.
60























 (IX)         R1, R2 = Aryl
Design and Synthesis ...
Pyrazolines...
59
SECTION-I : SYNTHESIS AND BIOLOGICAL EVALUATION OF 3-
A R Y L - 5 - { 1 ' , N - P H E N Y L - 3 ' - [ p - ( M E T H Y LT H I O )
PHENYL] - P Y R A Z O L - 4 ' - Y L } -PYRAZOLINES
SECTION-II : SYNTHESIS AND BIOLOGICAL EVALUATION OF 1,N-
ACETYL-3-ARYL-5-{1',N-PHENYL-3'-[p-(METHYL
THIO)PHENYL]-PYRAZOL-4'-YL}-PYRAZOLINES
SECTION-III : SYNTHESIS AND BIOLOGICAL EVALUATION OF 1,N-










synthesis and antibacterial activity of pyrazole and pyrazoline derivatives of
diazepam.
Recently, Gokhan N. et al.
61
 have synthesized the pyrazoline derivatives of
1-N-substituted thiocarbamoyl-3-phenyl-5-thienyl-2-pyrazolines as MAO inhibitors.
Matysiak J. et al.
62
 have reported some novel pyrazoline derivatives as antimycotic
activity of N-azolyl-2,4-dihydroxythiobenzamides. Tabarelli Z. et al.
63
 have prepared
some pyrazole derivative showed activity of antinociceptive effect of novel
pyrazolines in mice.
With a view to get better therapeutic agent, it was contemplated to synthesize
pyrazoline derivatives to enhance the overall activity of resulting compounds which














SYNTHESIS AND BIOLOGICAL EVALUATION OF 3-AR YL-5-{1 ' ,N-
P H E N Y L - 3 ' - [ p - ( M E T H Y LT H I O ) P H E N Y L ] - P Y R A Z O L - 4 ' - Y L } -
PYRAZOLINES
Pyrazolines are endowed with vast biological activities. Looking at their
versatile therapeutic importance and with an aim to getting better drug, it was
considered worthwhile to synthesize some new pyrazolines bearing 1,N-phenyl-3-
[p-(methylthio)phenyl]-4-formyl pyrazole nucleus. The preparation of 3-aryl-5-{1',N-
phenyl-3 ' - [p-(methyl thio)phenyl] -pyrazol -4 ' -y l}- pyrazolines (II) have been
under taken by cyclocondensation of chalcones Type (I) with hydrazine hydrate.
The constitution of the synthesized products have been characterized by using
elemental analyses, infrared and 1H-nuclear magnetic resonance spectroscopy and
further supported by mass spectroscopy.
All the products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains
and antifungal activity towards Aspergillus niger at a concentration of 40 µg/ml.
The biological activities of the synthesized compounds were compared with standard
drugs. The details have been cited in Part-I, Section-I (D).
Moreover, some selected compounds have been evaluated for their in vitro
biological assay towards a strain of Mycobacterium tuberculosis H37Rv at  a
concentration of 6.25 µg/ml using Rifampin as a standard drug which have been
tested at Tuberculosis Antimicrobial Acquisition Co-ordinating Facility (TAACF),















Type - (II), R = Aryl




Alkane C-H str. (asym.) 2958 2975-2950 64
-CH3 C-H str. (sym.) 2879 2880-2860  , ,
C-H i.p.def. (asym.) 1436 1470-1435  , ,
C-H o.o.p. def.(sym.) 1350 1390-1370  , ,
Aromatic C-H  str. 3074 3090-3030 65
C=C str. 1583 1540-1480  , ,
C-H i.p. (def.) 1172 1125-1090  , ,
C-H o.o.p. (def) 812 835-810  , ,
Pyrazole C=N str. 1583 1610-1590 65
moiety C-N str. 1245 1230-1020  , ,
Pyrazole ring C-N str. 1095 1230-1020  , ,
N-H str. 3340 3320-3140  , ,
C=N str. 1606 1650-1550  , ,
C-H (CH2) str. 2839 2850-2790  , ,
Halide C-Cl str. 617 600-800 64
Type      Ref.
        Reported














































IR SPECTRAL STUDIES OF 3-(p-CHLOROPHENYL)-5-{1',N-PHENYL-
3'-[p-(METHYLTHIO)PHENYL]-PYRAZOL-4'-YL}-PYRAZOLINE
Instrument  : SHIMADZU-FT-IR 8400-Spectrophotometer ; Frequency range : 4000-400 cm-1
(KBr disc.)
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1 2.5 3 H singlet Ar-SCH3     -
2 2.95-3.03 1 H d,d Ar-Hl     -
3 3.36-3.45 1 H d,d Ar-Hm     -
4 5.06-5.14 1 H triplet Ar-Hk     -
5 7.23-7.26 1 H triplet Ar-Hc     -
6 7.28-7.30 2 H d,d Ar-Ha,e     -
7 7.32-7.35 2 H doublet Ar-Hg,g’ Jgf=6.9
8 7.42-7.44 2 H doublet Ar-Hb,d     -
9 7.55-7.59 2 H doublet Ar-Hj,j’ Jji=7.8
10 7.60-7.63 2 H doublet Ar-Hf,f ’ Jfg=6.6
11 7.68-7.71 2 H doublet Ar-Hi,i’ Jij=7.8




    (dppm)
 Relative No.
  of protons
Multiplicity Inference    J Value






















NMR SPECTRAL STUDIES OF 3-(p-CHLOROPHENYL)-5-{1',N-PHENYL-
3'-[p-(METHYLTHIO)PHENYL]-PYRAZOL-4'-YL}-PYRAZOLINE
Instrumental Standard : TMS; Solvent: CDCl3 ; Instrument : BRUKER Spectrometer (300MHz)








































































































SYNTHESIS AND BIOLOGICAL EVALUATION OF 3-AR YL-5-{1 ' ,N-
P H E N Y L - 3 ' - [ p - ( M E T H Y LT H I O ) P H E N Y L ] - P Y R A Z O L - 4 ' - Y L } -
PYRAZOLINES
[A] Synthesis of 1-(p-Anisyl)-3-{1'-N-phenyl-3'-[p-(methylthio)phenyl]-
pyrazol-4'-yl}-2-propene-1-one
See, Part-I, Section-I (C)
[B] Synthesis of 3-(p-Chlorophenyl)-5-{1',N-phenyl-3'-[p-(methylthio)
phenyl]-pyrazol-4'-yl}-pyrazoline
A mixture of  1-(p-chlorophenyl)-3-{1'-N-phenyl-3'-[p-(methylthio)phenyl]-
pyrazol-4'-yl}-2-propene-1-one (4.30 gm, 0.01 mol) and hydrazine hydrate
(1 gm, 0.02 mol) in methanol (25 ml) was refluxed for 8 hrs. The reaction mixture
was poured on to crushed ice. The product was isolated and crystallized from
dioxane. Yield, 65%, m.p. 165o C; Anal. Calcd. for C25H21ClN4 S ; Required:
C, 67.48%; H, 4.76%; N, 12.59%; Found: C, 67.43%; H, 4.73%; N, 12.55%.
Similarly other 3-aryl-5-{1',N-phenyl-3 ' - [p-(methylthio)phenyl]-pyrazol-
4 ' -y l} -pyrazolines were prepared. The physical data are recorded in Table No. 2
[C] Antimicrobial  act ivi ty  of 3-Aryl-5-{1',N- phenyl-3 ' - [p-(methylthio)
phenyl]-pyrazo l -4 ' -y l } - pyrazolines
Antimicrobial testing was carried out as described in Part-I, Section-I (D).
The zone of inhibition of the test solutions are recorded in Graphical Chart No. 2
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2a 182289 PT-14 C6H5 - Alamar H37R v >6.25 11
2b 182290 PT-15 4-Cl-C6H4 - Alamar H37R v >6.25 00
2c 182291 PT-16 4-Br-C6H4 - Alamar H37R v >6.25 00
2d 182292 PT-17 4-CH3-C6H4- Alamar H37R v >6.25 12
2e 182293 PT-18 4-OCH3-C6H4 - Alamar H37R v >6.25 10
2f 182294 PT-19 4-SCH3-C6H4- Alamar H37R v >6.25 35
2g 182295 PT-20 4-OH-C6H4- Alamar H37R v >6.25 81
2h 182296 PT-21 2-OH-C6H4- Alamar H37R v >6.25 24
2i 182297 PT-22 3,5-(Br)2-4-OH-C6H2- Alamar H37R v >6.25 00
2j 182298 PT-23 4-NO2-C6H4- Alamar H37R v >6.25 10
2k 182299 PT-24 3-NO2-C6H4- Alamar H37R v >6.25 00
2l 182300 PT-25 4-NH2-C6H4- Alamar H37R v >6.25 08




   ID
 Corp
   ID
R Assay    Mtb
  Strain
     %
Inhibi.
   MIC
 mg/ml
TAACF, Southern Research Institute
Primary Assay Summary Report
NAID/Southern Research Institute/GWL Hansen’s Disease Centre/Colorado State
University proprietary Information








ANTITUBERCULAR ACTIVITY O F 3 - A RYL-5-{1' ,N-PHENYL-3'- [ p-
(METHYLTHIO)PHENYL]-PYRAZOL-4'-YL}-PYRAZOLINES





































































SYNTHESIS AND BIOLOGICAL EVALUATION OF 1,N-ACETYL-3-ARYL-
5-{1' ,N-PHENYL-3'- [ p-(METHYLTHIO)PHENYL] -PYRAZOL-4 ' -YL}-
PYRAZOLINES
Pyrazoline derivatives represent one of the most active classes of compounds
having a wide spectrum of biological activities. Looking to the interesting properties
of pyrazolines it was considered worthwhile to synthesize a series of pyrazolines of
type-(III) for obtaining biologically potent agents which were prepared by reacting
chalcones with hydrazine hydrate in glacial acetic acid.
The constitution of the synthesized products have been characterized by using
elemental analyses, infrared and 1H-nuclear magnetic resonance spectroscopy and
further supported by mass spectroscopy.
All the products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains
and antifungal activity towards Aspergillus niger at a concentration of 40 µg/ml.
The biological activities of the synthesized compounds were compared with standard
drugs. The details have been cited in Part-I, Section-I (D).
Moreover, some selected compounds have been evaluated for their in vitro
biological assay towards a strain of Mycobacterium tuberculosis H37Rv at  a
concentration of 6.25 µg/ml using Rifampin as a standard drug which have been
tested at Tuberculosis Antimicrobial Acquisition Co-ordinating Facility (TAACF),


















Type-(III) R = Aryl




Alkane C-H str. (asym.) 2923 2975-2950 64
-CH3 C-H str. (sym.) 2852 2880-2860  , ,
C-H i.p.def.(asym.) 1446 1470-1435  , ,
C-H o.o.p. def.(sym.) 1359 1390-1370  , ,
Aromatic C-H  str. 3053 3090-3030 65
C=C str. 1504 1540-1480  , ,
C-H i.p. (def.) 1172 1125-1090  , ,
C-H o.o.p. (def) 833 835-810  , ,
Pyrazole C=N str. 1604 1610-1590 65
moiety C-N str. 1033 1230-1020  , ,
Pyrazole ring C-N str. 1261 1230-1020  , ,
N-H str. 3433 3320-3140  , ,
C=N str. 1564 1650-1550  , ,
C-H(CH2) str. 2852 2850-2790  , ,
N-COCH3 str. 1658 1660 64
Halide C-Cl str. 761 600-800  , ,
Type     Ref.
        Reported
Frequency in cm-1 Vibration
Mode
IR SPECTRAL STUDIES OF 1,N-ACETYL-3-(p-CHLOROPHENYL)-5-














































Instrument  : SHIMADZU-FT-IR 8400-Spectrophotometer ; Frequency range : 4000-400 cm-1
(KBr disc.)






    (dppm)
 Relative No.
  of protons
Multiplicity Inference    J Value
    In Hz
1 2.44 3 H singlet Ar-COCH3     -
2 2.49 3 H singlet Ar-SCH3     -
3 3.02-3.09 1 H d,d Ar-Hl     -
4 3.54-3.64 1 H d,d Ar-Hm     -
5 3.88 3 H singlet Ar-OCH3     -
6 5.83-5.88 1 H d,d Ar-Hk     -
7 6.88-6.92 2 H doublet Ar-Hj,j’ Jji=11.5
8 7.22-7.24 1 H triplet Ar-Hc     -
9 7.27-7.28 2 H doublet Ar-Hg,g’ Jgf=8.1
10 7.37-7.43 2 H doublet Ar-Hb,d     -
11 7.58-7.61 2 H doublet Ar-Hi,i’ Jij=11.4
12 7.66-7.86 2 H multiplet Ar-H(a,e)     -
13 7.86-7.13 2 H doublet Ar-Hf,f ’ Jfg=8.1

























NMR SPECTRAL STUDIES OF 1,N-ACETYL-3-(p-METHOXYPHENYL)-5-
{ 1 ' , N - P H E N Y L - 3 ' -[ p-(METHYLTHIO)PHENYL] - P Y R A Z O L - 4 ' - Y L } -
PYRAZOLINE
Instrumental Standard : TMS; Solvent: CDCl3 ; Instrument : BRUKER Spectrometer (300MHz)

















































































































SYNTHESIS AND BIOLOGICAL EVALUATION OF 1,N-ACETYL-3-ARYL-
5-{1' ,N-PHENYL-3'- [ p-(METHYLTHIO)PHENYL] -PYRAZOL-4 ' -YL}-
PYRAZOLINES
[A] Synthesis of 1-(p-Anisyl)-3-{1'-N-phenyl-3'-[p-(methylthio)phenyl]-
pyrazol-4'-yl}-2-propene-1-one
See, Part-I, Section-I (C)
[B] Synthesis  of  1,N-Acetyl-3-(p-methoxyphenyl)-5-{1',N-phenyl-3'-[p-
(methylthio)phenyl]-pyrazol-4'-yl}-pyrazoline
To a solution of 1-(p-methoxyphenyl)-3-{1',N-phenyl-3'- [p-(methylthio)
phenyl]-pyrazol-4'-yl}-2-propene-1-one (4.26 gm, 0.01 mol), in 25 ml of ethanol,
hydrazine hydrate (0.5 gm, 0.01 mol) and glacial acetic (10 ml) was added and
refluxed for 8 hrs. The content were poured on to crushed ice,  thus the product
was separated and crystallized from ethanol. Yield, 60%. m.p. 132oC. Anal. Calcd.
for C28H26N4O2S ; Required: C, 69.69%; H, 5.43%; N, 11.61%; Found: C, 69.64%;
H, 5.41%; N, 11.58%.
Similarly other 1 , N - ace ty l -3 -a ry l -5 - {1 ' ,N-pheny l -3 ' - [p-(methylthio)
phenyl]pyrazol-4'-yl}-pyrazolines  were prepared. The physical data are recorded
in Table No. 3
[C] Antimicrobial activity of 1,N-Acetyl-3-aryl-5-{1',N-phenyl-3'-[p-
(methylthio)phenyl]pyrazol-4'-yl}-pyrazolines
Antimicrobial testing was carried out as described in Part-I, Section-I (D).
The zone of inhibition of the test solution are recorded in Graphical Chart No. 3.
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3a 182315 PT-40 C6H5 - Alamar H37R v >6.25 07
3b 182316 PT-41 4-Cl-C6H4 - Alamar H37R v >6.25 00
3c 182317 PT-42 4-Br-C6H4 - Alamar H37R v >6.25 13
3d 182318 PT-43 4-CH3-C6H4- Alamar H37R v >6.25 11
3e 182319 PT-44 4-OCH3-C6H4 - Alamar H37R v >6.25 86
3f 182320 PT-45 4-SCH3-C6H4- Alamar H37R v >6.25 00
3g 182321 PT-46 4-OH-C6H4- Alamar H37R v >6.25 10
3h 182322 PT-47 2-OH-C6H4- Alamar H37R v >6.25 00
3i 182323 PT-48 3,5-(Br)2-4-OH-C6H2- Alamar H37R v >6.25 31
3j 182324 PT-49 4-NO2-C6H4- Alamar H37R v >6.25 00
3k 182325 PT-50 3-NO2-C6H4- Alamar H37R v >6.25 00
3l 182326 PT-51 4-NH2-C6H4- Alamar H37R v >6.25 05




   ID
 Corp
   ID
R Assay    Mtb
  Strain
   MIC
 mg/ml
TAACF, Southern Research Institute
Primary Assay Summary Report
NAID/Southern Research Institute/GWL Hansen’s Disease Centre/Colorado State
University proprietary Information
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Inhibi.
ANTITUBERCULAR ACTIVITY OF 1,N-ACETYL-3-ARYL-5-{1',N-PHENYL-
3'-[p-(METHYLTHIO)PHENYL]-PYRAZOL-4'-YL}-PYRAZOLINES










































































SYNTHESIS AND BIOLOGICAL EVALUATION OF 1,N-PHENYL-3-ARYL-
5-{1' ,N-PHENYL-3'- [ p-(METHYLTHIO)PHENYL] -PYRAZOL-4 ' -YL}-
PYRAZOLINES
Looking to the interesting therapeutic activities of pyrazoline, it was
considered worthwhile to synthesize compounds bearing 1,N-phenyl-3-[p-
(methylthio)phenyl]-4-formyl pyrazole moiety linked to the pyrazoline nucleus.
Pyrazolyl pyrazoline of Type (IV) have been prepared by the action of 1-aryl-3-
{1',N-phenyl-3 ' - [p-(methylthio)phenyl]-pyrazol-4 ' -y l}-2- propene-1-ones with
phenylhydrazine in presence of piperidine.
The constitution of the synthesized products have been characterized by using
elemental analyses, infrared and 1H-nuclear magnetic resonance spectroscopy and
further supported by mass spectroscopy.
All the products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains
and antifungal activity towards Aspergillus niger at a concentration of 40 µg/ml.
The biological activities of the synthesized compounds were compared with standard
drugs. The details have been cited in Part-I, Section-I (D).
Moreover, some selected compounds have been evaluated for their in vitro
biological assay towards a strain of Mycobacterium tuberculosis H37Rv at  a
concentration of 6.25 µg/ml using Rifampin as a standard drug which have been
tested at Tuberculosis Antimicrobial Acquisition Co-ordinating Facility (TAACF),
















Type-(IV) R = Aryl




Alkane C-H str. (asym.) 3008 2975-2950 64
-CH3 C-H str. (sym.) 2854 2880-2860  , ,
C-H i.p.def. (asym.) 1400 1470-1435  , ,
C-H o.o.p. def. (sym.) 1326 1390-1370  , ,
Aromatic C-H  str. 3043 3090-3030 65
C=C str. 1596 1540-1480  , ,
C-H i.p. (def.) 1132 1125-1090  , ,
C-H o.o.p. (def) 817 835-810  , ,
Pyrazole C=N str. 1596 1610-1590 65
moiety C-N str. 1218 1230-1020  , ,
Pyrazole ring C-N str. 1093 1230-1020  , ,
N-H str. 3211 3320-3140  , ,
C=N str. 1569 1650-1550  , ,
C-H(CH2) str. 2854 2850-2790  , ,
Halide C-Cl str. 750 600-800 64
Type     Ref.
        Reported











































IR SPECTRAL STUDIES OF 1,N-PHENYL-3-(p-CHLOROPHENYL)-5-
{1' ,N-PHENYL-3'- [ p-(METHYLTHIO)PHENYL] -PYRAZOL-4' -YL}-
PYRAZOLINE
Instrument  : SHIMADZU-FT-IR 8400-Spectrophotometer ; Frequency range : 4000-400 cm-1
(KBr disc.)






    (dppm)
 Relative No.
  of protons
Multiplicity Inference    J Value
    In Hz
1 2.5 3 H singlet Ar-SCH3     -
2 3.15-3.22 1 H d,d Ar-Hl     -
3 3.76-3.85 1 H d,d Ar-Hm     -
4 5.48-5.54 1 H d,d Ar-Hk     -
5 6.79-6.84 1 H triplet Ar-Hp     -
6 7.08-7.10 2 H multiplet Ar-Hg,g’ Jgf=6.00
7 7.16-7.25 3 H multiplet Ar-H(b,c,d)     -
8 7.32-7.39 6 H multiplet   Ar-H(o,q,n,r,a,e)     -
9 7.61-7.62 2 H doublet Ar-Hi,i’ Jij=5.98
10 7.63-7.65 2 H doublet Ar-Hf,f ’ Jfg=6.00



























NMR SPECTRAL STUDIES OF 1,N-PHENYL-3-(p-CHLOROPHENYL)-5-
{ 1 ' , N - P H E N Y L - 3 ' -[ p-(METHYLTHIO)PHENYL] - P Y R A Z O L - 4 ' - Y L } -
PYRAZOLINE
Instrumental Standard : TMS; Solvent: CDCl3 ; Instrument : BRUKER Spectrometer (300MHz)

















































































































SYNTHESIS AND BIOLOGICAL EVALUATION OF 1,N-PHENYL-3-ARYL-
5-{1' ,N-PHENYL-3'- [ p-(METHYLTHIO)PHENYL] -PYRAZOL-4 ' -YL}-
PYRAZOLINES
[A] Synthesis of 1-(p-Anisyl)-3-{1'-N-phenyl-3'-[p-(methylthio)phenyl]-
pyrazol-4'-yl}-2-propene-1-one
See, Part-I, Section-I (C)
[B] Synthesis  of  1 ,N-Phenyl-3-(p-chlorophenyl)-5-(1' ,N-phenyl-3'-[p-
(methylthio)phenyl]-pyrazol-4'-yl)-pyrazoline
To a solution of  1-(p-chlorophenyl)-3-{1'-N-phenyl-3'-[p-(methylthio)
phenyl]-pyrazol-4'-yl}-2-propene-1-one (4.30 gm, 0.01 mol), phenylhydrazine (1.08
gm, 0.01 mol) in 25 ml methanol was refluxed for 12 hrs. in presence of basic catalyst
piperidine. The reaction product was poured on to crushed ice, thus the crude product
was isolated and crystallized from dioxane. Yield, 61%, m.p. 265oC; Anal. Calcd.
for C31H25ClN4S ; Required: C, 71.45%; H, 4.84%; N, 10.75%; Found: C, 71.41%;
H, 4.82%; N, 10.72%.
Similarly other 1,N-phenyl-3-aryl-5-{1',N-phenyl-3'-[p-(methylthio)phenyl]-
pyrazol-4'-yl}-pyrazolines were prepared. The physical data are recorded in Table
No. 4
[C] Antimicrobial  act ivity of  1,N-Phenyl-3-aryl-5-{1',N-phenyl-3'-[p-
(methylthio)phenyl]-pyrazol-4'-yl}-pyrazolines
Antimicrobial testing was carried out as described in Part-I, Section-I (D).
The zone of inhibition of the test solutions are recorded in Graphical Chart No. 4
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4a 182302 PT-27 C6H5 - Alamar H37R v >6.25 00
4b 182303 PT-28 4-Cl-C6H4 - Alamar H37R v >6.25 06
4c 182304 PT-29 4-Br-C6H4 - Alamar H37R v >6.25 00
4d 182305 PT-30 4-CH3-C6H4- Alamar H37R v >6.25 00
4e 182306 PT-31 4-OCH3-C6H4 - Alamar H37R v >6.25 16
4f 182307 PT-32 4-SCH3-C6H4- Alamar H37R v >6.25 19
4g 182308 PT-33 4-OH-C6H4- Alamar H37R v >6.25 00
4h 182309 PT-34 2-OH-C6H4- Alamar H37R v >6.25 11
4i 182310 PT-35 3,5-(Br)2-4-OH-C6H2- Alamar H37R v >6.25 02
4j 182311 PT-36 4-NO2-C6H4- Alamar H37R v >6.25 13
4k 182312 PT-37 3-NO2-C6H4- Alamar H37R v >6.25 00
4l 182313 PT-38 4-NH2-C6H4- Alamar H37R v >6.25 06




   ID
 Corp
   ID
R Assay    Mtb
  Strain
     %
Inhibi.
   MIC
 mg/ml
TAACF, Southern Research Institute
Primary Assay Summary Report
NAID/Southern Research Institute/GWL Hansen’s Disease Centre/Colorado State
University proprietary Information








ANTITUBERCULAR ACTIVITY OF 1,N-PHENYL-3-ARYL-5-{1',N-PHENYL-
3'-[p-(METHYLTHIO)PHENYL]-PYRAZOL-4'-YL}-PYRAZOLINES
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    PART - III
STUDIES ON
CYANOPYRIDINES




Pyridine with different functional groups, exhibit wide range of applications
in the field of pharmaceutical, agriculture and dyes. Although many substituted
pyridine compounds like other heterocyclic compounds are synthesized with their
functional group present from a cyclic compounds. The simple pyridine compounds
are prepared by the cyclization of aliphatic raw material. The availability of
3-cyanopyridines nicotinamide and nicotinic acid make possible their use as synthetic
intermediates.
Most derivatives are prepared by manipulation of pyridine and its simple
homologues in a manner similar to chemistry of the benzenoid chemistry. However
the simple pyridine compounds are prepared by the cyclization of aliphatic raw
materials.
SYNTHETIC ASPECT
Different method for the preparation of 3-cyanopyridines are available in
literature.
1-7
 The well known methods are:
1. Samour and co-workers prepared substituted cyanopyridines by the
condensation of chalcones with ethyl acetoacetate and malononitrile in
presence of ammonium acetate.
8,9
2. J. M. Babbit et al.
10
 have synthesized 3-cyano pyridines by cyclocondensation
of cyanoacetamide with ethyl acetoacetate in presence of base.
3. Substituted cyanopyridine derivatives were also prepared from 3-substituted
phenyl pyrazolone derivatives with malononitrile.
11
4. Ege and co-workers prepared 2-amino-3-cyanopyridine derivatives using
arylidene malononitrile + lithium isopropyl amide and DMF dichloride.
12,13
5. Sakurai and Midorikaw
14,15
 have reported that malononitrile reacts with a,b -
unsaturated ketones to give 2-amino-3-cyano-4,6-disubstituted pyridines(III).




The reaction proceeds through conjugated addition of active methylene
compounds to the a,b -unsaturated system as shown below.
THERAPEUTIC IMPORTANCE
Cyanopyridine have attracted considerable attention as they appeared of
interest to possess antibacterial, anticholestermic, antifungal, antihypertensive and
antidiabetic activities. Hammana Abou and co-workers
16
 have studied anticancer
and anti HIV activity of 3-cyanopyridines. Abdallah Navine et al.
17
 have prepared
cyanopyridine derivatives which showed analgesic and antiinflammatory activity.
Manna Fedele and co-workers
18
 have reported the antiinflammatory activity of
3-cyanopyridines. H. Yoshida et al.
19
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activity of 3-cyanopyridine derivatives. Abd El-Galil and co-workers
20
 have prepared
3-cyanopyridines (IV) and studied their pharmacological activity. Gadaginamath
and co-workers
21
 have synthesized various cyanopyridyl derivatives (V) and
documented their variety of biological activities.
S. V. Roman et al.
22
 have synthesized 2-amino-3-cyanopyridines and reported
their biological activity. El-Taweel and co-workers
23
 have prepared cyanopyridine
derivatives and showed their significant biological activity. A. R.  Parikh et al.
24
have synthesized 3-cyanopyridine derivatives as antimicrobial agent.
Hussan M. and co-workers
25
 have prepared 3-cyanopyridines and reported
their pharmacological activity. Pyachenko U. D. et al.
26
 have synthesized some
cyanopyridines which are useful in the treatment of retroviral disease.
Thiele Kurt et al.
27
 have studied the analgesic activity of substituted
3-cyanopyridines. N. Latif and co-workers
28
 have reported the antibacterial and
antifungal activity of 2-amino-3-cyano-4,6-disubstituted pyridines. M. Bernard
et al.
29
 have reported the anticonvulsant activity of 3-cyanopyridines. D. G. Bhatt et
al.
30
 have prepared 3-cyanopyridines as an immunosuppressive agent. U. Teu and
co-workers
31
 have shown cyanopyridine as agrochemical fungicides.
J. A. Vann Allan et al.
32
 have prepared fused heterocyclic 3-cyanopyridine
(VI). Abu and co-workers
33
 have prepared novel fused cyanopyridines (VII) for the
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K. Kadlec and Hanslian
34
 showed that 2-methyl-3-nitro-4-methoxyethyl-5-
cyano-6-chloro pyridines caused occupational eczema in Vitamin B6 factory
workers.  Rigterink and Raymond
35
 have studied the pesticidal activity of
3-cyanopyridines. M. R. Pavia et al.
36
 have prepared N-substituted 2- aminopyridines
which possess anticonvulsant property. 3-Cyanopyridines reported by L. Castedo
et al.
37  showed a minimum inhibitory concentration of 1.56 µg/ml against S. aureus.
J. J. Baldwin
38-40





 have studied the bacteriostatic effect of some
substituted 3-cyanopyridines. Francis and co-workers
43
 have studied the effect of
some substituted pyridines on the growth of the walker carcinosarcome-256 in tissue
culture. Barton et al.
44
 have reported fungicidal and insecticidal properties.
W. Hoefling and co-workers
45
 have studied 3 and 4-cyanopyridines as tuberculosis
arresting agents.
W. Von Benbenburg and co-workers
46
 have synthesized 2-amino-3,6-
disubstituted pyridines as antiepileptic agents. V. Scott and E. Joseph
47,48
 have
prepared 2-amino-3-cyanopyridine derivatives which were found to be useful as
antipsoriasis pharmaceuticals.
Dipeptidyl peptidase (DPP-IV) inhibition has the potential to become a
valuable therapy for diabetes. Edwin B. Villhauer and co-workers
49
 have reported
the first use of solid-phase synthesis in the discovery of a new DPP-IV inhibitor
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One compound, NVP-DPP728 (VIII), is profiled as a potent, selective and
shortacting DPP-IV inhibitor that has excellent oral bioavailability and potent
antihyperglycemic activity.
Marco J. L. et al.
50
 have synthesized acetylcholinesterase inhibitors. Moustafa
M. A. et al.
51
 have prepared antibacterial agents. Eduardo H. S. Sousa et al.
52
documented thionicotinamide coordinated to the a model system for the in vitro
activation of thioamides antituberculosis drugs. Rosentreter Ulrich et al.
53
 have
synthesized a new cyanopyridine as receptor agonists in the treatment of cardiac or
urogenital disease cancer, inflammation, neurodegenerative disease(IX). Gary T.
Wang and co-workers
54
 have synthesized of o-trifluoromethylbiphenyl substituted
2-amino-nicotinonitriles as inhibitors of farnesyl transferase(X)
In view of therapeutic activities shown by cyanopyridines, it was contemplated
to synthesize some new cyanopyridines in search of agents possessing higher
biological activity with least side effect have been described as under.
SECTION-I    : SYNTHESIS AND BIOLOGICAL EVALUATION OF 2 -






























SYNTHESIS AND BIOLOGICAL EVALUATION OF 2-AMINO-3-CYANO-4-
{1',N-PHENYL-3'-[p-(METHYLTHIO)PHENYL]-PYRAZOL-4'-YL}-6-ARYL-
PYRIDINES
In the past years, considerable evidence has been accumulated to demonstrate
the efficiency of cyanopyridines. To further assess the potential of such class of
compounds, cyanopyridine derivatives of Type (V) have been synthesized by the
condensation of malononitrile and ammonium acetate with 1-aryl-3-{1',N-phenyl-
3 ' -[p-(methylthio)phenyl]-pyrazol-4 ' -y l}-2-propene-1-ones.
The constitution of the synthesized products have been characterized by using
elemental analyses, infrared and 1H-nuclear magnetic resonance spectroscopy and
further supported by mass spectroscopy.
All the products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains
and antifungal activity towards Aspergillus niger at a concentration of 40 µg/ml.
The biological activities of the synthesized compounds were compared with standard

















Type-(V) R = Aryl




Alkane C-H str. (asym.) 2922 2975-2950 55
-CH3 C-H str. (sym.) 2852 2880-2860  , ,
C-H i.p.def.(asym.) 1436 1470-1435  , ,
Aromatic C-H  str. 3070 3090-3030 56
C=C str. 1502 1540-1480  , ,
C-H o.o.p. (def) 825 835-810  , ,
Pyrazole C=N str. 1596 1600-1650 56
moiety C-N str. 1220 1220-1020  , ,
Pyridine ring N-H str. 3242 3350-3250  , ,
C = N str. 2210 2240-2120  , ,
C=N str. 1637 1650-1600  , ,
Halide C-Cl str. 758 800-750 55
Amine NH2 str 3392 3200-3400  , ,
Type     Ref.
        Reported
Frequency in cm-1 Vibration
Mode

















































Instrument  : SHIMADZU-FT-IR 8400-Spectrophotometer ; Frequency range : 4000-400 cm-1
(KBr disc.)
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1 2.5 3 H singlet Ar-SCH3     -
2 6.88-6.93 1 H doublet Ar-Hc     -
3 7.24-7.26 2 H doublet Ar-Hg,g' Jgf=8.6
4 7.30-7.33 2 H doublet Ar-Hi,i' Jij=8.1
5 7.37 2 H singlet Ar-NH2     -
6 7.39-7.42 2 H triplet Ar-H(b,d)     -
7 7.50-7.54 5 H multiplet Ar-Hf,f ' (k,a,e) Jfg=8.4
8 7.76-7.81 2 H doublet Ar-Hj,j' Jji=8.1




    (dppm)
 Relative No.
  of protons
Multiplicity Inference    J Value























NMR SPECTRAL STUDIES OF 2-AMINO-3-CYANO-4-{1',N-PHENYL-3'-[p-
(METHYLTHIO)PHENYL] -PYRAZOL-4'-YL}-6-( p-CHLOROPHENYL)-
PYRIDINE
Instrumental Standard : TMS; Solvent: CDCl3 ; Instrument : BRUKER Spectrometer (300MHz)
















































































































SYNTHESIS AND BIOLOGICAL EVALUATION OF 2-AMINO-3-CYANO-4-
{1',N-PHENYL-3'-[p-(METHYLTHIO)PHENYL]-PYRAZOL-4'-YL}-6-ARYL-
PYRIDINES
[A] Synthesis of 1-(p-Anisyl)-3-{1'-N-phenyl-3'-[p-(methylthio)phenyl]-
pyrazol-4'-yl}-2-propene-1-one
See, Part-I, Section-I (C).
[B] Synthes is  of  2-Amino-3-cyano-4-{1 ' ,N-phenyl -3 ' -[p- (methyl thio)
phenyl]-pyrazol-4'-yl}-6-(p-chlorophenyl)-pyridine
A mixture of 1-(p-chlorophenyl)-3-{1'-N-phenyl-3'-[p-(methylthio)phenyl]-
pyrazol-4'-yl}-2-propene-1-one (4.30 gm, 0.01 mol), malononitrile (0.66 gm, 0.01
mol) and ammonium acetate (6.16 gm, 0.08 mol) dissolved in methanol was refluxed
for 12 hrs. The reaction mixture was poured on to crushed ice and kept overnight.
Thus the solid separated was isolated and crystallized from ethanol. Yield, 88%,
m.p. 208oC. Anal. Calcd. for C28H20ClN5S ; Required: C, 68.08; H, 4.08; N, 14.18
%; Found: C, 68.04; H, 4.05; N, 14.13%.
Similarly other 2-amino-3-cyano-4-{1',N-phenyl-3'-[p-(methylthio)phenyl] -
pyrazol-4'-yl}-6-aryl-pyridines were synthesized. The physical data are recorded in
Table No. 5
[C] Antimicrobial activity of 2-Amino-3-cyano-4-{1',N-phenyl-3'-[p-(methyl
thio)phenyl]-pyrazol-4'-yl}-6-aryl-pyridines
Antimicrobial testing was carried out as described in Part-I, Section-I (D).
The zone of inhibition of the test solutions are recorded in Graphical Chart No. 5.
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    PART - IV
STUDIES ON
CYANOPYRIDONES




Pyridones, which belongs to an important group of heterocyclic compounds
have been extensively explored for their applications in the field of medicine.
Pyridones, with a carbonyl group at position 2 (I) have been subject of extensive
study in recent past. Numerous reports have appeared in the literature, which
highlight their chemistry and use.
Pyridones are derivatives of pyrimidines with carbonyl group at 2-position (I).
Some 2-pyridones are physiologically as well as pharmacologically important which
are as under, eg. amrinone (H), ciclopirox (TO) and methylprylon (IV).
SYNTHETIC ASPECT
1. K. Folkers and S. A. Harris
1 have synthesized 3-cyano-2-pyridone by
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2. M. A. Sluyter and co-workers
2
 have prepared fused 2-pyridones.
3. G. Simchen and G. Entemman
3
 have synthesized 2-pyridone in which the ring
nitrogen comes from a nitrile group in acyclic precursor.
THERAPEUTIC IMPORTANCE


















 have prepared heteroaryl pyridones as GABA a,b  ligands (V).
Pednekar
15
 have synthesized fused 2-pyridone derivatives (VI), (VII) and (VIII) as
useful heterocyclic moieties as they possess broad spectrum of biological activities
such as antiviral, CNS depressant, bactericidal and ulcer inhibitor.















Morishita Koji et al.
22





























(V) (VI) (VII) (VIII)
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derivatives (IX) possessing cholesterol acyltransterase (ACAT) inhibitory activity
and are useful for the treatment of hyperlipidemia and arteriosclerosis.
M. G. Nizamuddin et al.
23
 have prepared cyanopyridone derivatives (X) and
documented their antifungal activity.
Tanaka Akira et al.
24
 have prepared pyrazolo pyridone derivatives (XI).
Peter and co-workers
25
 have described pyridinylmethyl substituted pyridines
and pyridones as angiotensin II antagonist. H. Posnes
26
 have synthesized 2-pyridones































 have prepared 2-pyridone derivatives (XII) and (XIII) which possess
insecticidal and pesticidal activity.
Upadhyay et al.
29
 have documented cyanopyridone derivatives, which showed
antifungal, and antileishmanial activities. E. Amer
30
 prepared 3-cyano-2-pyridone
derivatives (XIV) displaying high antimicrobial activity. Abou El-Fotooh and
co-workers.
31
 have demonstrated pyridones (XV) as anticancer agent.
Thus significant biological properties associated with cynopyridones
derivative have aroused considerable interest to design the compounds with better
drug  potentials and to study their pharmacological profile, the synthesis and
therapeutic evaluation of them, have been described as under.
SECTION I : SYNTHESIS AND BIOLOGICAL EVALUATION OF 3 -














































SYNTHESIS AND BIOLOGICAL EVALUATION OF 3-CYANO-4-{1',N-
PHENYL-3'-[p-(METHYLTHIO)PHENYL]-PYRAZOL-4'-YL}-6-ARYL-1,2-
DIHYDRO-2-PYRIDONES
Pyridone derivatives have remarkable therapeutic activity. Taking this into
consideration, we have undertaken the preparation of pyridone derivatives by the
condensation of chalcones of Type-(I) with ethylcyanoacetate in presence of
ammonium acetate as shown under.
The constitution of the synthesized products have been characterized by using
elemental analyses, infrared and 1H-nuclear magnetic resonance spectroscopy and
further supported by mass spectroscopy.
All the products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains
and antifungal activity towards Aspergillus niger at a concentration of 40 µg/ml.
The biological activities of the synthesized compounds were compared with standard
drugs. The details have been cited in Part-I, Section-I (D).
Moreover, some selected compounds have been evaluated for their in vitro
biological assay towards a strain of Mycobacterium tuberculosis H37Rv at  a
concentration of 6.25 µg/ml using Rifampin as a standard drug which have been
tested at Tuberculosis Antimicrobial Acquisition Co-ordinating Facility (TAACF),






















Alkane C-H str. (asym.) 2918 2975-2950 32
-CH3 C-H str. (sym.) 2850 2880-2860  , ,
C-H i.p.def. (asym.) 1436 1470-1435  , ,
Aromatic C-H  str. 3082 3090-3030 33
C=C str. 1546 1540-1480  , ,
C-H o.o.p. (def) 821 835-810  , ,
Pyrazole C=N str. 1598 1600-1650  33
moiety C-N str. 1095 1220-1020  , ,
Pyridone ring C = N str. 2225 2240-2120  , ,
C=O str. 1637 1760-1655  , ,
N-H str. 3404 3450-3250  , ,
N-H def. 1598 1650-1580  , ,
Halide C-Cl str. 752 800-750 32
Type     Ref.
        Reported
Frequency in cm-1 Vibration
Mode




















































Instrument  : SHIMADZU-FT-IR 8400-Spectrophotometer ; Frequency range : 4000-400 cm-1
(KBr disc.)
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1 2.5 3 H singlet Ar-SCH3     -
2 6.25 1 H singlet Ar-Hl     -
3 7.29-7.32 2 H doublet Ar-Hj,j' Jji=8.4
4 7.36-7.38 2 H triplet Ar-H(b,d)     -
5 7.39-7.42 2 H doublet Ar-Hg,g' Jgf=9.1
6 7.50-7.55 5 H multiplet Ar-Hi,i' (a,c,e) Jij=8.1
7 7.63 1 H singlet Ar-NH     -
8 7.82-7.85 2 H doublet Ar-Hf,f ' Jfg=9.0




    (dppm)
 Relative No.
  of protons
Multiplicity Inference    J Value























NMR SPECTRAL STUDIES OF 3-CYANO-4-{1' ,N-PHENYL-3'- [ p-
(METHYLTHIO)PHENYL]-PYRAZOL-4'-YL}-6-(p-CHLOROPHENYL)-1,2-
DIHYDRO-2-PYRIDONE
Instrumental Standard : TMS; Solvent: CDCl3 ; Instrument : BRUKER Spectrometer (300MHz)
















































































































SYNTHESIS AND BIOLOGICAL EVALUATION OF 3-CYANO-4-{1' ,N-
PHENYL-3'-[p-(METHYLTHIO)PHENYL]-PYRAZOL-4'-YL}-6-ARYL-1,2-
DIHYDRO-2-PYRIDONES
[A] Synthesis of 1-(p-Anisyl)-3-{1'-N-phenyl-3'-[p-(methylthio)phenyl]-
pyrazol-4'-yl}-2-propene-1-one
See, Part-I, Section-I (C).
(B) Synthesis of 3-Cyano-4-{1',N-phenyl-3'-[p-(methylthio)phenyl]-pyrazol-
4'-yl}-6-p-chlorophenyl-1,2-dihydro-2-pyridone
To a solution of 1-(p-chlorophenyl)-3-{1'-N-phenyl-3'-[p-(methylthio)phenyl]-
pyrazol-4'-yl}-2-propene-1-one (4.30 gm, 0.01 mol), ethyl cyanoacetate (1.13 gm,
0.01 mol) and ammonium acetate (6.16 gm, 0.08 mol) in absolute alcohol was
refluxed for 10 hrs. The reaction mixture was poured on to crushed ice and product
was isolated and crystallized from ethanol. Yield 70%, m.p. 165°C. Anal. Calcd.
for C28H19ClN4OS ; Required: C, 67.94; H, 3.87; N, 11.32 %; Found: C, 67.90;
H, 3.83; N, 11.28 %.
Similarly other 3-cyano-4-{1',N-phenyl-3'-[p-(methylthio)phenyl]-pyrazol-
4'-yl}-6-p-chlorophenyl-1,2-dihydro-2-pyridones were prepared. The physical data
are recorded in Table No. 6
(C) Antimicrobial activity of 3-Cyano-4-{1',N-phenyl-3'-[p-(methylthio)
phenyl]-pyrazol-4'-yl}-6-aryl-1,2-dihydro-2-pyridones
Antimicrobial testing was carried out as described in Part-I, Section-I(D).
The zone of inhibition of the test solutions are recorded in Graphical Chart No. 6
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6a 182328 PT-53 C6H5 - Alamar H37R v >6.25 00
6b 182329 PT-54 4-Cl-C6H4 - Alamar H37R v >6.25 04
6c 182330 PT-55 4-Br-C6H4 - Alamar H37R v >6.25 16
6d 182331 PT-56 4-CH3-C6H4- Alamar H37R v >6.25 28
6e 182332 PT-57 4-OCH3-C6H4 - Alamar H37R v >6.25 61
6f 182333 PT-58 4-SCH3-C6H4- Alamar H37R v >6.25 10
6g 182334 PT-59 4-OH-C6H4- Alamar H37R v >6.25 50
6h 182335 PT-60 2-OH-C6H4- Alamar H37R v >6.25 00
6i 182336 PT-61 3,5-(Br)2-4-OH-C6H2- Alamar H37R v >6.25 24
6j 182337 PT-62 4-NO2-C6H4- Alamar H37R v >6.25 08
6k 182338 PT-63 3-NO2-C6H4- Alamar H37R v >6.25 00
6l 182339 PT-64 4-NH2-C6H4- Alamar H37R v >6.25 75




   ID
 Corp
   ID
R Assay    Mtb
  Strain
     %
Inhibi.
   MIC
 mg/ml
TAACF, Southern Research Institute
Primary Assay Summary Report










TABLE  NO. 6
ANTITUBERCULAR ACTIVITY OF 3-CYANO-4-{1',N-PHENYL-3'-[p-(METHYL
THIO)PHENYL]-PYRAZOL-4'-YL}-6-ARYL-1,2-DIHYDRO-2-PYRIDONES
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    PART - V
STUDIES ON
INDAZOLES




Cyclohexenones are derivatives of cyclohexane with carbonyl group at
position-1 and double bond at position-2 (I).  There are different types of
cyclohexenone derivatives but the greatest difference in structure and properties is
exerted by the groups attached to carbon atom.
Cyclohexenone is the parent of a series of compounds that is important in
agricultural and medicinal chemistry. Cyclohexenones can be conveniently
synthesized by the treatment of a,b -unsaturated carbonyl compounds with
ethylacetoacetate in basic media.
In recent years cyclohexenone derivatives have gained lots of interest because
of its prominent pharmaceutical properties.
SYNTHETIC ASPECT
Different methods for the preparation of cyclohexenone derivatives have been
described in literature.
1-14
(I) Eman H. A. et al.
15
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(II) Shklyaev A.  S .  e t  a l .
16
 have  syn thes i zed  1 - subs t i tu t ed  (R ,S) -8 - (2 -
methoxy-5-methylphenyl)-3,3,9-trimethyl-2-azaspiro[4,5]deca-1,7- dien-6-
ones (III).
(III) A review of the earlier literature by Gerald et al.
17
 described representative
synthetic procedure of cyclohexenone derivatives (IV).
(IV) Page Philip C. and co-workers
18






















The addition reaction between ethylacetoacetate and a ,b-unsaturated ketone
give cyclohexenone via. Michael addition. This reaction has been carried out in




 in acetone. During the
reaction, nucleophilic addition of carbanion take place to the C=C of the acceptor.
The a ,b-unsaturated compound is known as acceptor and ethylacetoacetate is known
as donor.
THERAPEUTIC EVALUATION
Cyclohexenone and its derivatives are widely used in pharmaceutical industry.
Considerable interest has been shown in the chemistry of cyclohexenones due to




























































Recently, antimicrobial activity of cyclohexenones have been studied by
Salama and Atshikh.
29 
Cyclohexenone possess neutropeptide g-receptor antagonist




have demonstrated cyclohexenone as GABA a 5 receptor ligands for enhancing
coagulating properties. Cyclohexenones possess inhibitory activity against the growth
of lettuce seeding found by Kimura and co-workers.
32
Cyclohexenones have various medicinal applications as an antiarrhythmic
activity
33
 of some cyclohexenone derivatives have been investigated. Cyclohexenone
possess cardiovascular, osteoporosis, menpausal symptoms, estrogen dependent,
cancer activities, which was reported by Jacobsen Poul et al.
34
Cyclohexenone and its derivatives have been prepared and reported as broad










 etc. Alekseeva L. M. and co-workers
41
 have
synthesized cyclohexenone derivatives which are useful as neurotropic activity.
Toshiyuki et al.
42
 have prepared some novel cyclohexenone and screened for their
allergy inhibitor, antithrombotic platelet aggregation inhibitors and fibrinogen
antagonist activity.
The presence of pesticidal activity among cyclohexenone derivatives is well
documen ted .  The  compound  2 -{ (E ,Z) -1 - [ (2R ,S ) -2 - (4 -ch lo rophenoxy)
propoxyimino]butyl}-3-hydroxy-5-thian-3-yl)cyclohex-2-en)-one (VI) has been
marketed under the name of ‘Profoxydim’ as an herbicides.


















Eddington N. D. et al.
43
 have synthesized ethyl 4-[(substituted phenyl)amino]-
6 -methy l -2 -oxocyc lohex-3-ene-1-ca rboxy la tes  (VI I )  and  sc reened  the i r
anticonvulsant activity. Cragoe, Edward J. et al.
44
 have prepared 2,3-dihydro-5-(3-
oxo-2-cyclohexen-1-yl)-2-benzofurancarboxylic acids (VIII) and their salts which
are used in the treatment of brain injury.
Indazole or benzopyrazoles a heterocyclic ring system in which a benzene
ring is fused to two carbon atoms of a pyrazole ring , is capable of existing in three
tautomeric forms (I, II, III).
45
 Although the chemistry of indazoles has been
extensively studied, they have not been found in natural products and are at the

















 are available for the preparation of indazoles. Some of
these are as under.
(I) Another synthesis is that due to Ainsworth (1957).
(II) Qui-Guo Fu et al.
52
 have reported that in presence of PPA 2,6-dialkoxyl or
hydroxyl acetophenone hydrazones were cyclized to indazoles.
(III) Recently, a facile synthesis of substituted indazoles from 2-acyl aryl
mesylates and hydrazine was described by Carom Stephane et al.
53
(IV) Indazole s may conveniently be prepared by heating o-nitroso-N-benzol
toluidine in benzene solution.
(V) Shri Niwas and co-workers
54
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(VI) Okhim L. Yu et al.
55
 have synthesized some indazole derivatives by heating
benzylidene aniline derivatives in DMF.
(VII) The most frequently used route for synthesis of indazole ring system consists




It is revealed from the literature survey that indazole derivatives are better
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Furthermore, Fukunaga K. et al.
74
 have reported 3-[2-[4-(3-chloro-2-
methylphenyl)-1-piperazinyl]ethyl]-5,6-dimethoxy-1-(4-imidazolylmethyl)-1H-
indazole dihydrochloride, a novel calmodulin antagonist, possesses neuro protective
activity. Mosti L. et al.
75
 have documented novel N-substituted 1-amino-3-[1-
methyl(phenyl)-1H-indazol-4-yloxy]-propen-2-ol as potential antiarrhythmic, local
anaesthetic and analgesic agents. Lee F. Y. and co-workers
76
 have synthesized
1-benzyl-3-(5’hydroxymethyl-2’-furyl)indazole analogues as novel antiplatelet
agents. Pinna G. A. et al.
77 have synthesized bisbenzo[g]indazol-3-carboxamides
and related dimers and checked their antiproliferative activity.
Ooe Takanon et al.
78
 have prepared some indazole derivatives which showed
activity for enhancing macrophage phagocytosis, improving immunity and antitumor
activity. Yamaguchi Masahisa et al.
79









Moreover, Effland Richard Charles et al.
71
 have synthesized 3-(pyridylamino)-
indazoles(IV) and reported their use as antidepressants and anxiolytics. Some
sulfonyl indazoles (V) synthesized by Duzinska Usarewicz et al.
72
 have found to
possess antiinflammatory activity. Butera John et al.
73
 have prepared some indazole












(IV)    (V)
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novel antiasthametic agents with dual activities of thromboxane A2 synthetase
inhibitors and bronchodialtion. The remarkable cytotoxic activity of indazole
derivatives have been reported by Aran Vincente J et al.
80
The indazoles have attracted considerable attention in the last 25 years,
because of several commercially useful drugs contain pyrazole ring system. For
example Antipyrine  (VI) has potent antipyretic activity. Similarly Butazolidine (VII)
has proved a powerful antiinflammatory drug used for rheumatic patients.
Pyrazofurin (VIII) shows activity against a number of viruses. Moreover,
Ethylchlozate (IX) is used as a plant growth regulators.
Recently, Nishino, Shigehide et al.
81 
 have prepared 3-carboxy-5-(1-carboxy
ethyl)indazole (X) which was used as intermediate for the preparation pesticides.
Stack, Gary Paul and co-workers
82
 have prepared antipsychotic aminomethyl
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Moreover, Hwang I. T. et al.
83
 have synthesized some new 2-phenyl-4,5,6,7-
tetrahydro-2H-indazole derivatives as paddy field herbicides. Tanitame A. et al.
84
have reported the design, synthesis and structure-activity relationship studies of
novel indazole analogues as DNA gyrase inhibitors with Gram-positive antibacterial
activity(XII).  Nasr M. N. et  al .
85
 have prepared some novel 3,3a,4,5,6,7-
hexahydroindazole and arylthiazolylpyrazoline derivatives as antiinflammatory
agents. Pinna G. A. et al.
86
 have described the synthesis of chromophore-modified
bis-benzo[g]indole carboxamides synthesis and antiproliferative activity of
bis-benzo[g]indazole-3-carboxamides.
Recently, Abouzid K. A. et al.
87
 have synthesized as antiinflammatory activity
of novel indazolones. Wang Q. et al.
88
 have described the synthesis and herbicidal
activity of 2-cyano-3-substituted-pyridinemethylaminoacrylates. Wang Q. et al.
89
have synthesized and herbicidal activity of 2-cyano-3-(2-chlorothiazol-5-
yl)methylaminoacrylates. Kakimoto T. et al.
90
 have prepared some novel 3,3a,5,9b-
tetrahydro-2H-furo[3,2-c][2] benzopyran derivatives: synthesis of chiral glycol
benzyl ether herbicides. Ikeguchi M. et al.
91
 have documented the synthesis and
herbicidal activity of new oxazinone herbicides with a long-lasting herbicidal
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In light of wide varieties of biological activities exhibited by cyclohexenones
and indazoles, it appeared of interest to synthesize cyclohexenones and indazole
derivatives, in order to achieving compounds having better therapeutic activity
described as under.












SYNTHESIS AND BIOLOGICAL EVALUATION OF ETHYL-6- {1 ' ,N-
PHENYL-3'-[ p-(METHYLTHIO)PHENYL] -PYRAZOL-4' -YL}-2-OXO-4-
ARYLCYCLOHEX-3-ENE-1-CARBOXYLATES
Cyclohexenone derivatives have considerable attention in view of their
potential pharmacological properties such as antimicrobial, anticonvulsant,
anticancer, etc. led by these considerations, the preparation of cyclohexenone
derivatives of Type-(VII) has been undertaken. The synthesis was carried out by
the condensation of 1-aryl-3-{1',N-phenyl-3 ' -[p-(methylthio)phenyl]-pyrazol-
4 ' -y l}-2-propene-1-ones of Type-(I) with ethyl acetoactate shown in presence of




 shown as under.
The structure elucidation of synthesized compounds have been done on the
basis of elemental analyses, infrared and 1H nuclear magnetic resonance spectroscopy
and further supported by mass spectrometry.
All the compounds have been evaluated for their in vitro biological assay
like antibacterial activity towards gram positive and gram negative bacterial strains
and antifungal activity towards Aspergillus niger at a concentration of 40 µg/ml.



















Type-(VII)     R = Aryl




Alkane C-H str. (asym.) 2923 2975-2950 92
-CH3 C-H str. (sym.) 2852 2880-2860  , ,
C-H i.p.def. (asym.) 1438 1470-1435  , ,
Aromatic C-H  str. 3072 3090-3030 93
C=C str. 1504 1540-1480  , ,
C-H o.o.p. (def) 823 835-810  , ,
Pyrazole C=N str. 1598 1600-1650 93
moiety C-N str. 1151 1220-1020  , ,
cyclohe- C=O str. of ester 1732 1750-1725  , ,
-xenone C=O str. of 1672 1720-1690 92
cyclohexenone
Halide C-Cl str. 754 800-750   ,,
Type     Ref.
        Reported
Frequency in cm-1 Vibration
Mode





















































Instrument  : SHIMADZU-FT-IR 8400-Spectrophotometer ; Frequency range : 4000-400 cm-1
(KBr disc.)
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1 1.09-1.18 3 H triplet -OCH2CH3      -
2 2.5 3 H singlet Ar-SCH3      -
3 2.69-2.82 1 H d-d Ar-Hl      -
4 2.90-3.08 1 H d-d Ar-Hm      -
5 3.67-3.76 1 H doublet Ar-Hk      -
6 4.05-4.17 3 H multiplet     -OCH2CH3,o      -
7 6.46-6.51 1 H singlet Ar-Hn      -
8 7.30-7.33 4 H multiplet Ar-H(jj’,gg’)      -
9 7.37-7.39 3 H multiplet Ar-H(a,c,e)      -
10 7.43-7.48 2 H triplet Ar-H(b,d)      -
11 7.62-7.65 2 H doublet Ar-Hii’ Jgf = 8.4
12 7.69-7.72 2 H doublet Ar-Hff’ Jji = 8.4




    (dppm)
 Relative No.
  of protons
Multiplicity Inference    J Value
    In Hz
NMR SPECTRAL STUDIES OF ETHYL-6-{1',N-PHENYL-3'-[ p-(METHYL






























Instrumental Standard : TMS; Solvent: CDCl3 ; Instrument : BRUKER Spectrometer (300MHz)






























































































































SYNTHESIS AND BIOLOGICAL EVALUATION OF ETHYL-6- {1 ' ,N-
PHENYL-3'-[ p-(METHYLTHIO)PHENYL] -PYRAZOL-4' -YL}-2-OXO-4-
ARYLCYCLOHEX-3-ENE-1-CARBOXYLATES
[A] Synthesis of 1-(p-Anisyl)-3-{1'-N-phenyl-3'-[p-(methylthio)phenyl]-
pyrazol-4'-yl}-2-propene-1-one
See [A] Part-I, Section-I (C).
(B) Synthesis of Ethyl-6-{1',N-phenyl-3'-[p-(methylthio)phenyl]-pyrazol-4'-
yl}-2-oxo-4-(p-chlorophenyl)-cyclohex-3-ene-1-carboxylate
To a solution of 1-(p-chlorophenyl)-3-{1'-N-phenyl-3'-[p-(methylthio)
phenyl]-pyrazol-4'-yl}-2-propene-1-one (4.30 gm, 0.01 mol), ethyl acetoacetate
(2.60 gm, 0.02 mol) and potassium carbonate (0.05 mol) in acetone was added. The
reaction mixture was stirred for 12 hrs. The content was cooled and poured on to
crushed ice. The product was isolated and crystallized from ethanol. Yield 85 %,
m.p. 265oC Anal. Calcd. for C31H27ClN2O3S; Requires: C, 68.56; H, 5.01; N,
5.16 % Found: C, 68.52; H, 5.00, N, 5.13 %.
Similarly other ethyl-6-{1' ,N-phenyl-3'-[p-(methylthio)phenyl] -pyrazol-4'-
yl}-2-oxo-4-aryl-cyclohex-3-ene-1-carboxylates were  prepared. The physical data
are recorded in Table No. 7.
(C) Antimicrobial activity of Ethyl-6-{1',N-phenyl-3'-[p-(methylthio)phenyl]-
pyrazol-4'-yl}-2-oxo-4-aryl-cyclohex-3-ene-1-carboxylates
Antimicrobial testing were carried out as described in Part-I, Section-I(D).
The zones of inhibition of test solution are reported in Graphical Chart No. 7.
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SYNTHESIS AND BIOLOGICAL EVALUATION OF 4-{1',N-PHENYL-3'-[p-
(METHYLTHIO)PHENYL]-PYRAZOL-4'-YL}-6-ARYL- 2 , 3a,4,5-TETRA
HYDRO-3H-INDAZOL-3-ONES
Various derivatives of indazole exhibit interesting biological properties like
anticancer, antiinflammatory, anticonvulsant, antipyretic etc. With a view to prepare
more potential drug value compounds, we have carried out the synthesis of indazole
derivatives of Type-(VIII), which have been prepared by the condensation of
cyclohexenone derivatives of Type-(VII) with hydrazine hydrate in presence of glacial
acetic acid, which have been briefed as under.
The constitution of the synthesized products have been characterized by using
elemental analyses, infrared and 1H-nuclear magnetic resonance spectroscopy and
further supported by mass spectroscopy.
All the products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains
and antifungal activity towards Aspergillus niger at a concentration of 40 µg/ml.
The biological activities of the synthesized compounds were compared with standard






















Type-(VIII)     R = Aryl
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IR SPECTRAL STUDIES OF 4-{1',N-PHENYL-3'-[ p-(METHYLTHIO)
PHENYL] - P Y R A Z O L - 4 ' - Y L } - 6 - (p- C H L O R O P H E N Y L ) -2 , 3a , 4 , 5 -
TETRAHYDRO-3H-INDAZOL-3-ONE
 Observed
Alkane C-H str. (asym.) 2981 2975-2950 92
-CH3 C-H str. (sym.) 2898 2880-2860  , ,
C-H i.p.def. (asym.) 1467 1470-1435  , ,
Aromatic C-H  str. 3024 3090-3030 93
C=C str. 1467 1540-1480  , ,
C-H i.p. (def) 1028 1070-1000  , ,
C-H o.o.p. (def) 835 835-810  , ,
Pyrazole C=N str. 1573 1600-1650 93
moiety C-N str. 1228 1220-1020  , ,
Indazole C=O str. 1672 1680-1640 92
Halide C-Cl str. 756 800-750  ,,
Type     Ref.
        Reported





















































Instrument  : SHIMADZU-FT-IR 8400-Spectrophotometer ; Frequency range : 4000-400 cm-1
(KBr disc.)
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1 2.5 3 H singlet Ar-SCH3      -
2 2.68-2.76 1 H d-d Ar-Hl      -
3 2.79-3.02 1 H d-d Ar-Hm      -
4 3.06-3.08 1 H doublet Ar-Ho      -
5 3.68-3.72 1 H singlet Ar-Hk      -
6 6.51 1 H singlet Ar-Hn      -
7 7.30-7.35 4 H multiplet Ar-H(jj ’ ,ii’ )      -
8 7.36-7.39 3 H multiplet Ar-H(a,c,e)      -
9 7.42-7.48 2 H triplet Ar-H(b,d)      -
10 7.62-7.65 2 H doublet Ar-Hgg’ Jgf = 9.01
11 7.68-7.72 2 H doublet Ar-Hff’ Jji = 9.00




    (dppm)
 Relative No.
  of protons
Multiplicity Inference    J Value
    In Hz
NMR SPECTRAL STUDIES OF 4-{1',N-PHENYL-3'-[p-(METHYLTHIO)



























Instrumental Standard : TMS; Solvent: CDCl3 ; Instrument : BRUKER Spectrometer (300MHz)


























































































































SYNTHESIS AND BIOLOGICAL EVALUATION OF 4-{1',N-PHENYL-3'-[p-
(METHYLTHIO)PHENYL]-PYRAZOL-4'-YL}-6-ARYL- 2 , 3a,4,5-TETRA
HYDRO-3H-INDAZOL-3-ONES
[A] Synthesis of 1-(p-Anisyl)-3-{1'-N-phenyl-3'-[p-(methylthio)phenyl]-
pyrazol-4'-yl}-2-propene-1-one
See Part-I, Section-I (C).
[B] Synthesis of Ethyl-6-{1',N-phenyl-3'-[p-(methylthio)phenyl]-pyrazol-4'-
yl}-2-oxo-4-(p-chlorophenyl)-cyclohex-3-ene-1-carboxylate
See Part-V, Section-I (B)
[C] Synthesis of 4-{1',N-Phenyl-3'-[p-(methylthio)phenyl]-pyrazol-4'-yl}-6-
(p-chlorophenyl)-2,3a,4,5-tetrahydro-3H-indazol-3-one
A mixture of ethyl-6-{1',N-phenyl-3'-[p-(methylthio)phenyl] -pyrazol-4'-yl}-
2-oxo-4-(p-chlorophenyl)-cyclohex-3-ene-1-carboxylate (5.43 gm, 0.01 mol) and
hydrazine hydrate (1.1 gm, 0.02 mol) was refluxed in ethanol (25 ml) containing 1-
3 ml glacial acetic acid, on a water bath for 5 hrs. The residue obtains after cooling
was filtered and crystallized from methanol. Yield 68%, m.p. 165°C. Anal. Calcd.
for C29H23ClN4OS ; Required: C, 68.16; H, 4.54; N, 10.96 %; Found: C, 68.12;
H, 4.50; N, 10.95.
Similarly other 4-{1',N-phenyl-3'- [p-(methylthio)phenyl] -pyrazol-4'-yl}-6-
aryl- 2,3a,4,5-tetrahydro-3H-indazol-3-ones were prepared. The physical data are
recorded in Table No. 8.
[D] Antimicrobial activity o f  4-{1' ,N-Phenyl-3'-[p-(methylthio)phenyl]-
pyrazol-4'-yl}-6-aryl-2,3a,4,5-tetrahydro-3H-indazol-3-ones
Antimicrobial testing were carried out as described in Part-I, Section-I (D).
The zones of inhibition of test solutions are recorded in Graphical Chart No. 8.
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    PART - VI
STUDIES ON
AMINO PYRIMIDINES




2-Aminopyrimidine is the most important member of all the diazine as this
ring system occurs widely in living organisms. Pyrimidine was first isolated by Gabriel
and Colman in 1899. 2-Amino pyrimidine and its derivatives represent one of the
most active class of compounds possessing a wide spectrum of biological activities.
Pyrimidine and its derivatives have gained prominence because of their
potential pharmaceutical values. Many pyrimidine derivatives play vital role in
many physiological action. They are among those molecules that make life possible
as being some of the building blocks of DNA and RNA. Pyrimidine is considered
to be a resonance hybrid of the charged and uncharged canonical structures, its




 synthesized 2-amino-pyrimidine by the reaction of chalcone
epoxides with guanidine carbonate in xylene.
2. Abd-El-galil E. Amr
2
 synthesized aminopyrimidines by the reaction of
chalcones with guanidine hydrochloride in the presence of NaOH.
3. The reaction of chalcone with guanidine hydrochloride in presence of
















3. Tyrosine kinase inhibitor
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7. Inhibitor of cellular proliferation
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Large number of drugs possess aminopyrimidine ring system. Well-known
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Peirre C. Wyss et al.
14
 have prepared some novel aminopyrimidines as novel
dihydrofolate reductase inhibitors. Aleem Gangjee et al.
15
 have described some
aminopyrimidines as potential dual inhibitors of thymidylate synthase, and
dihydrofalate reductase and as potential antitumor agents. Andre Rosowasky et al.
16
have reported aminopyrimidines as potent and selective inhibitors of dihydrofalate
reductase from three major opportunistic pathogens of AIDS. Tsutumi et al.
17
 have
documented aminopyrimidines as adenosine receptor antagonists.
Hernandez et al.
18
 and Secrist J. et al.
19
 have prepared aminopyrimidines
showing antitumor activity. Glazier A. et al.
20
 and Singh J.
21
 found aminopyrimidines
as ant iviral  agents .  Pan S.
22
 have prepared 2-methylthio-4-amino-6-(3,5-
diacetylphenyl-amino)-pyrimidines which show anti HIV activity in H9 cell cultures.









 have synthesized some aminopyrimidines which are useful
in  the t reatment  of  rotaviral  diseases .  Robson C.  e t  a l .
27
 have prepared
aminopyrimidine derivatives as antifungal agents in P9P and MRP over expressive
tumor cell lines. Leanne M. et al.
28
 have prepared aminopyrimidines and reported
them as antiviral agent.
Bargiotti, Alberto et al.
29
 have studied 1,7-disubstituted guanine derivatives
for their therapeutic use as telomerase inhibitors and anticancer agent. Bargiatli,
Alberto et al.
30

















 have synthesized some aminopyrimidines and tested for
endothelin antagonists. Suto M. et al.
32
 prepared some amino pyrimidines which
was found to possess antiinflammatory, anticancer, antirheumatoid activities. Gangjee
A. et al.
33
 have synthesized aminopyrimidines which possess antitumor activity.
Ugarkar B. et al.
34
 reported aminopyrimidines in the inhibition of cardiovascular
and cerebrovascular disorders.
Marie Gompel and co-workers
35
 have showed that meridianins inhibit various
protein kinases such as cyclin-dependent kinases, glycogen synthase kinase-3, cyclic
nucleotide-dependent kinases and casein kinase (III). Alistair H. et al.
36
 have
synthesized a novel series of aminopyrimidine IKK2 inhibitors have been developed
which show excellent in vitro  inhibition of this enzyme and good selectivity over
the IKK1 isoform. The relative potency and selectivity of these compounds have
been rationalized using QSAR and structure-based modelling (IV).
Aleem Gangjee et al.
37
 have prepared novel analogues, N-{4-[2-(2-amino-4-
ethylpyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl}-L-glutamic acid were designed and
synthesized as potential inhibitors of thymidylate synthase (TS) and dihydrofolate






-NH-DABOs) 4, 5 belonging to the dihydro-alkoxy-benzyl-oxopyrimidine












Meridianin A OH H H H
Meridianin B OH H Br H
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pyrimidine ring were designed as active against wild type human immunodeficiency
virus (HIV-1) and some relevant HIV-1 mutants(VI).
Viney Lather and co-workers
39
  have been proposed to predict the anti-HIV
activity of dihydro-alkylthio-naphthylmethyl-oxopyrimidines. These models are
capable of providing lead structures for development of potent but safe anti-HIV
agents(VII).
Looking to the diversified activities exhibited and in continuation of our
work on the synthesis of biologically active heterocycles, the synthesis and biological
evalution of aminopyrimidine derivatives have been described as under.
SECTION : I   SYNTHESIS AND BIOLOGICAL EVALUATION OF 2-
    AMINO-4-{1',N-PHENYL-3'-[ p-(METHYLTHIO)PHENYL]-

































SYNTHESIS AND BIOLOGICAL EVALUATION OF 2-AMINO-4-{1',N-
PHENYL-3'- [ p-(METHYLTHIO)PHENYL] -PYRAZOL-4' -YL}-6-ARYL-
PYRIMIDINES
Looking to the interesting pharmacological and agriculture activity of
pyrimidine ring system, it was considered worthwhile to synthesize some new
2- am i n o - 4 - {1 ' ,N-phenyl -3 ' -[p-(methylthio)phenyl] -pyrazol-4 ' -y l}-6-aryl -
pyrimidines  of Type (IX) to study their biological activities. Amino pyrimidine
derivatives have been prepared by the reaction of the chalcones of Type (I) with
guanidine hydrochloride in presence of ethanol shown as under.
The constitution of the synthesized products have been characterized by using
elemental analyses, infrared and 1H-nuclear magnetic resonance spectroscopy and
further supported by mass spectroscopy.
All the products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains
and antifungal activity towards Aspergillus niger at a concentration of 40 µg/ml.
The biological activities of the synthesized compounds were compared with standard














NH2 NH2 . HCl
NH
Ethanol
Type-(IX)     R = Aryl




Alkane C-H str. (asym.) 2918 2975-2950    40
-CH3 C-H str. (sym.) 2850 2880-2860     , ,
C-H i.p.def. (asym.) 1448 1470-1435     , ,
Aromatic C-H  str. 3053 3090-3030    41
C=C str. 1498 1540-1480     , ,
C-H o.o.p. (def) 815 835-810     , ,
Pyrazole C=N str. 1629 1600-1650     , ,
moiety C-N str. 1226 1220-1020     , ,
Primary amine N=H str. 3298 3559-3350    40
Pyrimidine C=N str. 1546 1580-1520    41
Type     Ref.
        Reported
Frequency in cm-1 Vibration
Mode
IR SPECTRAL STUDIES OF 2-AMINO-4- {1' ,N-PHENYL-3'- [ p-












































Instrument  : SHIMADZU-FT-IR 8400-Spectrophotometer ; Frequency range : 4000-400 cm-1
(KBr disc.)
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NMR SPECTRAL STUDIES OF 2-AMINO-4- {1' ,N-PHENYL-3'- [ p-
(METHYLTHIO)PHENYL] -PYRAZOL-4'-YL}-6- (p-CHLOROPHENYL)-
PYRIMIDINE
1 2.5 3 H singlet Ar-SCH3     -
2 6.90 1 H singlet Ar-Hk     -
3 7.26 2 H singlet Ar-NH2     -
4 7.32-7.40 5 H multiplet Ar-Hg,g’(a,c,e)     -
5 7.47-7.52 2 H triplet Ar-Hb,d     -
6 7.59-7.63 2 H doublet Ar-Hi,i’ Jij=8.1
7 7.68-7.72 2 H doublet Ar-Hf,f ’ Jij=11.1
8 7.81-7.84 2 H doublet Ar-Hj,j’ Jji=8.0




    (dppm)
 Relative No.
  of protons
Multiplicity Inference    J Value






















Instrumental Standard : TMS; Solvent: CDCl3 ; Instrument : BRUKER Spectrometer (300MHz)










































































































SYNTHESIS AND BIOLOGICAL EVALUATION  OF 2-AMINO-4-{1',N-
PHENYL-3'- [ p-(METHYLTHIO)PHENYL] -PYRAZOL-4' -YL}-6-ARYL-
PYRIMIDINES
[A] Synthesis of 1-(p-Anisyl)-3-{1'-N-phenyl-3'-[p-(methylthio)phenyl]-
pyrazol-4'-yl}-2-propene-1-one
See, Part-I, Section-I (C).
[B] Synthesis  of  2-Amino-4-{1',N-phenyl-3'-[p-(methylthio)phenyl]-
pyrazol-4'-yl}-6-(p-chlorophenyl)-pyrimidine
A mixture of 1-(p-chlorophenyl)-3-{1'-N-phenyl-3'-[p-(methylthio)phenyl]-
pyrazol-4'-yl}-2-propene-1-one (4.30 gm, 0.01 mol) and guanidine hydrochloride
(1.10 gm, 0.01 mol) was refluxed in ethanol on a water bath for 4-5 hrs. The reaction
mixture was poured on to crushed ice. The product was filtered and crystallized
from ethanol. Yield 68%, m.p. 298°C. Anal. Calcd. for C26H20ClN5S ; Required:
C, 66.44; H, 4.29; N, 14.90 %; Found: C, 66.41; H, 4.26; N, 14.86 %.
Similarly other 2-amino-4-{1',N-phenyl-3'-[p-(methylthio)phenyl] -pyrazol-
4'-yl}-6-aryl-pyrimidines were prepared. The physical data are recorded in Table
No. 9
[ C ] Antimicrobial activity o f  2-Amino-4-{1',N-phenyl-3'-[p-(methylthio)
phenyl]-pyrazol-4'-yl}-6-aryl-pyrimidines
Antimicrobial testing were carried out as described in Part-I Section-I (D).
The zones of inhibition of test solution are recorded in Graphical Chart No.9
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    PART - VII
STUDIES ON
THIAZOLIDINONES




Thiazolidinones, which belong to an important group of heterocyclic
compounds have been extensively explored for their applications in the field of
medicine. Thiazolidinones, with a carbonyl group at position 2 in structure (I) and
position 4 or 5 in structure(II) have been subjected of extensive study in the recent
past. Numerous reports have appeared in the literature which highlight their
chemistry and use.
4-Thiazolidinones are derivatives of thiazolidine with carbonyl group at
4-position (II). Substituent in the 2, 3 and 5 positions may be varied, but the greatest
different in structure and properties is exerted by the groups attached to carbon
atom at the 2-position and to nitrogen atom at the 3-position. The cyclic structure
was assigned after recognition of mercaptoacetic acid as a primary product of
hydrolysis of 3-phenyl-2-phenylimino-4-thiazolidinones.
1
A well known antibiotic, actithiazic acid (IV), isolated from a species of
streptomyces shows specific in vitro activity against M. tuberculosis, but it is
inactive in vivo probably due to antagonisation by biotin, bears the 4-thiazolidinone
skeleton
SYNTHETIC ASPECT
Several methods for the preparation of 4-thiazolidinones are narrated in
literature
2-10
1. R. Nath and K. Shanker
11
 have prepared 4-thiazolidinones by cyclization
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of N-aryl-N’-(2'-pyridyl)-thiocarbamide with chloroacetic acid.
2. I. D. Shah and J. P. Trivedi
12
 have synthesized thiazolidinones from 4-aryl
thiosemicarbazones by condensing them with chloroacetic acid, a -
bromopropionic and a -bromophenyl acetic acid.
3. M. Seeda et al.
13


























































The reaction of 4-thiazolidinones proceeds by the attacks of the chloroacetic
acid upon the C=S group, the tautomerism takes place with removal of HCl followed
by removal of water and subsequent cyclization.
THERAPEUTIC IMPORTANCE
Much research has been carried out with the aim to finding therapeutic values
of thiazolidinone moiety since their discovery. The thiazolidinones, substituted at 2








































































 reported synthesis and in vitro  antibacterial activity
of some 4-thiazolidinone derivatives. Goel et al.
40
 have synthesized thiazolidinone
derivatives and compared their antiinflammatory activity, ulcerogenic liability,
cardiovascular and CNS effects. In other study, some thiazolidinones have been
found to be promising antibacterial agent.
41,42
Siddique, Mohammed et al.
43
 have prepared substituted thiazolidinones (IV)
and reported their antibacterial, antifungal, antithyroid and amoebicidal properties.
Akama Tsutoma et al.
44
 have synthesized thiazolidinones as a Telomeres
inhibitors. S. Guniz Kucukguzel et al.
45
 have synthesized thiazolidinones as
antimicrobial and anticancer agent. S. K. Srivastava et al.
46
 have prepared new
thiazolidinones as antibacterial, antifungal, analgesic and diuretic agents.
Recently, Fujiwara Norio et al.
47
 have synthesized thiazolidinones as
antiinflammatory agent. Pfahl Magnus et al.
48












R2, R4, R5 = H
R3 = Me
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tested their phosphatase inhibitory and anticancer activity. Jag Mohan et al.
49
have
prepared thiazolidinones (V) and reported their antimicrobial activity.
Govindarajan R. et al.
50
 have synthesized thiazolidinones as antitubercular,
antifungal and antibacterial agent. Dinh T. H. et al.
51
 have prepared and reported
antibacterial and antifungal activity of thiazolidinones. Takagi Masae and co-
workers
52
 have synthesized thiazolidinones and screened for their antiinflammatory
activity. Ma Tonghui et al.
53
 have documented thiazolidinones as CFTR (cystic
fibrosis transmembrane conductance regulator) inhibitor.
Hassan et al.
54
 have prepared 2-imino-4-thiazolidinones which have been
found to possess antimicrobial activity. K. Mogilaiah and co-workers
55,56
 isolated
some 4-thiazolidinone derivatives and tested their antibacterial activity. G. S.
Godaginamath et al.
57
 also prepared thiazolidinone derivatives as antimicrobial agent.
R. S. Lodhi and co-workers
58
 have been synthesized and studied antimicrobial,
antiinflammatory and analgesic property of 4-thiazolidinone and arylidene derivatives
(VI).
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Recently, Dayam R. et al.
59
 have reported some novel thiazolidinone
derivatives as novel class of HIV- integrase inhibitors. Sonawane N. D. et al.
60
 have
synthesized some new thiaolidinone derivatives as in vivo pharmacology and
antidiarrheal efficacy of a thiazolidinone CFTR inhibitor in rodents. Shih M. H. et
al.
61
 have described the syntheses and evaluation of antioxidant activity of sydnonyl
substituted thiazolidinone and thiazoline derivatives(VII). Reigada D. et al.
62
 have
reported some novel thiazolidinone derivatives as release of ATP from retinal pigment
epithelial cells involves both CFTR and vesicular transport.
Moreover, Rao A. et al.
63
 have described some novel thiazolidinone derivatives
as 2-(2,6-dihalophenyl)-3-(pyrimidin-2-yl)-1,3-thiazolidin-4-ones as non-nucleoside
HIV-1 reverse transcriptase inhibitors. Muanprasat C. et al.
64
 have prepared some
new thiazolidinone derivatives as CFTR inhibitors
Furthermore, Salinas D. B. et al.
65
 documented the thiazolidinone derivatives
as CFTR inhibitor. Wang X. F. et al.
66
 have synthesized some novel thiazolidinone
derivatives described as new cystic fibrosis transmembrane conductance regulator
inhibitor on Cl-conductance in human sweat ducts. Ur F. et al.
67
 have constructed
some new 6-methylimidazo[2,1-b]thiazole-5-carbohydrazide derivatives and their
antimicrobial activities.
Recently, Maclean D. et al.
68
 have reported thiazolidinone library as agonists
of the follicle stimulating hormone receptor (VIII). Thiagarajah J. R. et al.
69
 have
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Thiagarajah J. R. et al.
70
 have been reported as intestinal ion and fluid secretion
by a small-molecule CFTR inhibitor. Taddei A. et al.
71
 have been constructed some
new thiazolidinone as CFTR inhibition.
These valid observations led us to explore thiazolidinones chemistry by
synthesizing its derivatives bearing pyrazole moiety of medicinal value in order to
achieve better therapeutic agents. It has been described in the following section.
SECTION - I   : SYNTHESIS AND BIOLOGICAL EVALUATION OF 2 -

















SYNTHESIS AND BIOLOGICAL EVALUATION OF 2-ARYLIMINO-3,N-
ARYL-5-{1',N-PHENYL-3'-[p-(METHYLTHIO)PHENYL]-4'-PYRAZOLYL
METHINO}-4-THIAZOLIDINONES
With a view to getting better therapeutic agents and considering the
association of various biological activities of thiazolidinone heterocycles, the
preparation of arylidenes of Type (X) have been undertaken by the condensation of
1,N-phenyl-3-[p-(methylthio)phenyl]-4-formyl pyrazole with different 2-arylimino-
3N-aryl-5H-4-thiazolidinones.
The constitution of the synthesized products have been characterized by using
elemental analyses, infrared and 1H-nuclear magnetic resonance spectroscopy and
further supported by mass spectroscopy.
All the products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains
and antifungal activity towards Aspergillus niger at a concentration of 40 µg/ml.
The biological activities of the synthesized compounds were compared with standard























Type-(X)     R = Aryl
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Alkane C-H str. (asym.) 2927 2975-2950 72
-CH3 C-H str. (sym.) 2854 2880-2860  , ,
C-H i.p.(def.) 1438 1470-1435  , ,
C-H o.o.p. (def) 1357 1395-1370  , ,
Aromatic C-H  str. 3031 3090-3030 73
C=C str. 1502 1540-1480  , ,
C-H i.p.(def.) 1095 1125-1090  , ,
C-H o.o.p.(def) 831 835-810  , ,
Pyrazole C=N str. 1598 1600-1650 72
moiety C-N str. 1226 1220-1020  , ,
Thiazolidinone C=O str. 1706 1760-1655 73
ring C-S-C str. 688 700-600  , ,
C-N str. 1164 1220-1020  , ,
C=N str. 1639 1640-1590  , ,
Type     Ref.
        Reported












































IR SPECTRAL STUDIES OF 2-(p-TOLYLIMINO)-3,N- (p-TOLYL)-5-{1',N-
PHENYL-3'-[p-(METHYLTHIO)PHENYL]-4'-PYRAZOLYL METHINO}-
4-THIAZOLIDINONE
Instrument  : SHIMADZU-FT-IR 8400-Spectrophotometer ; Frequency range : 4000-400 cm-1
(KBr disc.)
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1 2.36 3 H singlet Ar-CH3     -
2 2.47 3 H singlet Ar-CH3     -
3 2.52 3 H singlet Ar-SCH3     -
4 6.87-6.90 2 H doublet Ar-Hii’ Jij=8.1
5 7.16-7.19 2 H doublet Ar-Hjj’ Jji=8.1
6 7.34-7.38 7 H multiplet Ar-Hgg ’ ,ll’,ace     -
7 7.46-7.51 2 H triplet Ar-H(b,d)     -
8 7.58-7.61 2 H doublet Ar-Hmm’ Jml=8.1
9 7.73-7.76 2 H doublet Ar-Hff’ Jfg=8.1
10 7.82 1 H singlet Ar-Hk     -




    (dppm)
 Relative No.
  of protons
Multiplicity Inference    J Value
    In Hz




























Instrumental Standard : TMS; Solvent: CDCl3 ; Instrument : BRUKER Spectrometer (300MHz)


















































































































SYNTHESIS AND BIOLOGICAL EVALUATION OF 2-ARYLIMINO-3,N-
A R Y L - 5 - { 1 ' , N - P H E N Y L - 3 ' - [ p - ( M E T H Y L T H I O ) P H E N Y L ] - 4 ' -
PYRAZOLYLMETHINO}-4-THIAZOLIDINONES
[A] Synthesis of 1,N-Phenyl-3-[p-(methylthio)phenyl]-4-formyl pyrazole
See Part-I, Section-I (B).
[B] Synthesis of Bis-p-tolylthiourea
74
A mixture of p-toludine (2.14 gm, 0.02 mol) and carbondisulphide (2.28 gm,
0.03 mol) in absolute ethanol was heated at 40oC in waterbath for 12 hrs. The
mixture solidified on completion of reaction, the excess of the solvent was removed
by distillation. The crude product was treated with dil. HCl and crystallized from
rectified spirit. Yield, 80%, m.p. 154oC. Anal. Calcd. for C15H16N2S; Requires:
C, 70.31; H, 6.25; N, 10.93 %; found : C, 70.32; H, 6.27; N, 10.95 %.
[C] Synthesis of 2-p-Tolylimino-3-(p-tolyl)-5H-4-thiazolidinone
75
A mixture of Bis-p-tolylthiourea (2.56 gm, 0.01 mol), chloroaceticacid
(0.94 gm, 0.01 mol) and sodium acetate (1.23 gm, 0.015 mol) in glacial acetic acid
(30 ml) was refluxed on oil bath for 10 hrs. The reaction mixture was poured into
ice water and kept overnight. The crude product was isolated and crystallized from
glacial acetic acid. Yield, 80%, m.p. 145o C. Anal. Calcd. for C17H16N 2OS;
Requires: C, 68.89; H, 5.44; N, 9.45 %; found : C, 68.84; H, 5.42; N, 9.43 %.
[D] Synthesis of 2-(p-Tolylimino)-3,N-(p-tolyl)-5 - {1 ' ,N-phenyl -3 ' -[p-
(methy l th io )pheny l ]-4' - pyrazolylmethino}-4-thiazolidinone
A mixture of 1,N-phenyl-3-[p-(methylthio)phenyl]-4-formyl pyrazole
(2.94 gm, 0.01 mol), 2-p-tolylimino-3-(p-tolyl)-5H-4-thiazolidinone (2.96 gm, 0.01
mol) and fused sodium acetate (1.4 gm, 0.02 mol) in glacial acetic acid was refluxed
for 8 hrs. The solid thus obtained was filtered and crystallized from DMF. Yield
68%, m.p. 205oC. Anal. Calcd for C34H28N4OS2 ; Requires : C, 71.30; H, 4.93;
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N, 9.78 %; Found : C,71.25; H, 4.90; N, 9.75 %.
Similarly other 2-aryl-3,N-aryl- 5 - { 1 ' , N - p h e n y l - 3 ' - [ p - ( m e t h y l t h i o )
phenyl]-4 ' - pyrazolylmethino}-4-thiazolidinones  were prepared. The physical data
are recorded in Table No. 10.
[E] Antimicrobial activity of 2-Arylimino-3,N-ary l -5 -{1 ' ,N-phenyl -3 ' -[p-
(methylthio)phenyl]-4' - pyrazolylmethino}-4-thiazolidinones
Antimicrobial testing was carried out as described in Part-I, Section-I (D).
The zone of inhibition of the test solutions are recorded in Graphical Chart No. 10.
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    PART - VIII
STUDIES ON
PYRIMIDINONES




Pyrimidine derivatives occur in natural products
1
 like nucleic acids and
Vitamin-B have remarkable pharmaceutical importance because of their biological
activities.
2-6
 Several analogous of nucleic acids have been used as compounds that
interfere with the synthesis and functioning of nucleic acids, an example is
fluorouracil  which has been used in cancer treatment. Pyrimidines are among those
molecules that make life possible as being same of the building blocks of DNA and
RNA. Thiourea itself was one of the first new drug employed to depress, the
clinically over active thyroid in thyrotoxicosis but some of the cyclic thioureides
have since been found better suited. The most valuable have been thiouracil  and
it’s derivatives. All of these are prone of produce adverse reduction in susceptible
patients and found more potent and less likely to produce side effects and is being
used widely.
8
Some pyrimidines of physiologically as well  as pharmacologically
importance are as under: e.g. cytosine , beclmethrin (I), blasticidin  (II). Synthetic
pyrimidinone derivatives contribute much to the searchable l i terature of
pyrimidinone derivatives, in huge libraries owing to their wide applicability in
different fields.
SYNTHETIC ASPECT
Different methods for the synthesis of pyrimidinones have been cited in
the literature.
9
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2. By the condensation of b-dinitriles with thiourea and guanidines.
11
3. By the condensation of b-aldehydronitrile with formamidine and thiourea.
12
4. 2-Mercaptopyrimidines can be synthesized by G. N. Anderson
13
 through




 investigated that condensation of aromatic aldehyde with b-
ketoester and urea or thiourea yield the pyrimidine derivatives (III).
MECHANISM
The reaction of a,b -unsaturated system with urea leds to the formation of




















































































X = “O’’ or “S’’(III)




Pyrimidinone derivatives have proven to be of great importance in exhibiting



























 have suggested imidazolyl pyrimidinones as
antiviral. Nagamatsu et al.
40
 have prepared some new triazolo [3,4-c] pyrimidinone
as xanthin oxidase inhibitors. Andree Roland et al.
41
 have prepared oxazolyl uracil
as herbicidal and insecticidal. Yari M. M. and co-workers
42
 have investigated the
pyrimidinone derivatives which possess calcium antagonist activity.
Saxena A. K. and co-workers
43
 have prepared 2,6-disubstituted pyrimidinones
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Moreover, Azaryan et al.
44
 have synthesized pyrimidine diones as antitumor
agent. Krivongov and co-workers
45
 have synthesized pyrimidinone derivatives
possessing immunotropic and anti inflammatory activity.  Omer M. T. and
co-workers
46
 have prepared some new pyrimidinone derivatives showed moderate
activity against the growth of Bacillus subtilis, Staphylococcus aureus and
Aspergillus niger. Amuti Kofies et al.
47
 have suggested that pyrimidinones (V &
VI) as herbicidal and plant growth regulators.
Pyrimidinone derivatives
48,49
 (VII) have found to be calcium channel blocker
. Barbuliene M. M. et al.
50
 have synthesized pyrimidinones as antiinflammatory agent.
Bruce M. A. and co-workers
51
 prepared the dihydropyrimidinones (VIII) as
NPY antagonists. Sidler and Larsen
52
 have reported pyrimidinone derivatives (IX),
useful as an a -adrenergic receptor antagonists.



































 have prepared spiropyrimidinones as antibacterial. Drewes
and Wilhelm
54
 have synthesized pyrimidinones as herbicidal agents. Mona Mahram
and co-workers
55
 have documented pyrimidine derivatives as potent antimicrobial
and antitumor agents.
Recently, Amjad Ali et al.
56
 have prepared new fused pyrimidinones as
antimicrobial agents. Abd El-Galil et al.
57
 have synthesized pyrimidinone as
androgenic anabolic and antiinflammatory agents. Martin Bolli et al.
58
 have
documented pyrimidines as endothelin receptor antagonists. Patricia F. F. et al.
59
have described leukocyte functions inhibitor activity. Dumas Jacques et al.
60
 have
synthesized pyrimidinones and tested their hyderproliferative disorder activity.
Adenosine receptor antagonists pyrimidinones have been prepared by Tsutsumi Hideo
et al.
61
W. Jeffrey et al.
62
 assessed thiopyrimidine derivatives as HIV reverse
transcriptase inhibitors.  Thiopyrimidine derivatives are having numerous









 have reported thiopyrimidine derivatives (X) as a antimicrobial agent.
Gangjee Aleem
67
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Fggenweiler, Hans Michael et al.
68
 have prepared thieno [2,3-d] pyrimidine
derivatives as phosphodiesterase inhibitors. Patricia Fernandez-Ferri et al.
69 
have
synthesized pyrimidine derivatives as inhibitors of some leukocyte functions. Yadav
Bodke and S. S. Sangapure
70
 have prepared pyrimidine derivatives as biologically
active compounds. Dumas et al.
71
 have prepared some pyrimidine derivatives  for
treatment of hyperproliferative disorders. Chamanlal J. Shishoo et al.
72
 have
documented pyrimidine derivatives as antihistaminic activity.
Corbett et al.
73
 assessed thiopyrimidine derivatives as HIV reverse transcript
as inhibitors. Thiopyrimidine derivatives are having numerous pharmacological
activity like antagonists
74






 activity. C. J. Shishoo and co-workers
78
 have reported thiopyrimidine
derivatives as receptor antagonists. Recently, Abou El-Foltoh et al.
79
 have synthesized
thiopyrimidine derivatives which showed anticancer activity.
V. Peesapati et al.
80
 and Allimony have synthesized thiopyrimidine derivatives
81
and documented as potent antimicrobial agent. B. J. Ghiya et al.
82
 have synthesized
mercapto pyrimidine derivatives and screened for their anticancer, antitubercular
and anti HIV activities. S. A. Swelam
83
 have reported fluoro pyrimidines which
possess antitumor activity. Mohammad Nasrk et al.
84
 have prepared thiopyrimidine
nucleosides as antiviral agent. Danel et al.
85
 have synthesized some novel
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Gompel M. et al.
86
 have prepared new family of protein kinase inhibitors




a new series of potent, broad-spectrum non-nucleoside reverse transcriptase
inhibitors belonging to the DABO family. Yamamoto I. et al.
88
 have reported some
oxopyrimidines searching for the novel antagonist or agonist of barbiturates to the
sleep mechanism based on the uridine receptor. Huang Y. L. et al.
89
 have synthesized
non-classical antifolates, 5-(N-phenylpyrrolidin-3-yl)-2,4,6-triaminopyrimidines and
2,4-diamino-6(5H)-oxopyrimidines, synthesis and antitumor studies.
Shimizu T. and Kimura T. et al.
90
 have described of n(3)-substituted uridine
and related pyrimidine nucleosides and their antinociceptive effects in mice.
Sanmartin C. et al.
91
 have prepared and reported some of new symmetrical derivatives
as cytotoxic agents and apoptosis inducers. Agarwal A. and Kumar B. et al.
92
 have
synthesized 2,4,6-trisubstituted pyrimidine derivatives as pregnancy interceptive
agents.
Whittingham J. L. et al.
93
 have described as a platform for antimalarial drug
design and structural basis for the selectivity of a class of nucleoside inhibitors.
Han G. Z. et al.
94
 have documented the pyrimidine derivatives as anticancer actions
of 2-methoxyestradiol and microtubule-disrupting agents in human breast cancer.
Tack D. K. et al.
95
 have reported anthracycline Vs nonanthracycline adjuvant therapy
for breast cancer. Cano-Soldado P. et al.
96
 have described as interaction of nucleoside
inhibitors of HIV-1 reverse transcriptase with the concentrative nucleoside
transporter-1 (SLC28A1). Gompel M. et al.
97  have reported new family of protein
kinase inhibitors isolated from the ascidian aplidium meridianum. Junmei Wang et
al.
98
 have  prepared  h ie ra rch ica l  da tabase  sc reen ings  for  HIV-1  Reverse
Transcriptase.(XII)
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Thus, diverse biological activities have been encountered in compounds
containing pyrimidinone ring system. To further assess the potential of such type of
compounds, study of pyrimidinones have been carried out as under.


















SYNTHESIS AND BIOLOGICAL EVALUATION OF 6-ARYLIMINO-7,N-
A R Y L - 2 - O X O - 4 - { 1 ' , N - P H E N Y L - 3 ' -[ p - ( M E T H Y LT H I O ) P H E N Y L ]-
PYRAZOL-4 ' -YL}-1 ,2 ,3 ,4 -TETRAHYDRO-THIAZOLIDINO-[4 ,5 -d] -
PYRIMIDINES
In the past years considerable evidence has been accumulated to demonstrate
the efficiency of pyrimidinones. To further assess the potential of such class of
compounds, it was considered worthwhile to synthesize compounds bearing
2-arylimino-3,N-aryl-5-{1' ,N-phenyl-3 '-[p-(methylthio)phenyl]-4 '-pyrazolyl
methino}-4-thiazolidinones  nucleus  l inked to  the  pyr imidinone nucleus .
Pyrimidinones of Type (XI) have been prepared by the condensation of 2-arylimino-
3-aryl-5H-4-thiazolidinone, 1,N-phenyl-3-[p-(methylthio)phenyl]-4-formyl pyrazole
and urea in presence of catalytic amount of conc. HCl as shown under.
The constitution of the synthesized products have been characterized by using
elemental analyses, infrared and 1H-nuclear magnetic resonance spectroscopy and
further supported by mass spectroscopy.
All the products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains
and antifungal activity towards Aspergillus niger at a concentration of 40 µg/ml.
The biological activities of the synthesized compounds were compared with standard




























Type-(XI)     R = Aryl




Alkane C-H str. (asym.) 2920 2975-2950  99
-CH3 C-H str. (sym.) 2852 2880-2860   , ,
C-H i.p.(def.) 1438 1470-1435   , ,
C-H o.o.p. (def) 1352 1395-1370   , ,
Aromatic C-H  str. 3055 3090-3030 100
C=C str. 1529 1540-1480   , ,
C-H i.p.(def.) 1176 1125-1090   , ,
C-H o.o.p. (def) 825 835-810   , ,
Pyrazole C=N str. 1595 1600-1650 100
moiety C-N str. 1213 1255-1020   , ,
Pyrimidine C=O str. 1676 1750-1600   , ,
ring N-H str. 3361 3500-3350   , ,
C-N str. 1595 1650-1550   , ,
Ether C-S-C str. (asym.) 1286 1275-1200  99
C-S-C str. (sym.) 1008 1075-1020   , ,
Type     Ref.
        Reported


























































IR SPECTRAL STUDIES OF 6-PHENLIMINO-7,N-PHENYL-2-OXO-4-
{1' ,N-PHENYL-3'- [ p-(METHYLTHIO)PHENYL] -PYRAZOL-4' -YL}-
1,2,3,4-TETRAHYDRO-THIAZOLIDINO-[4,5-d]-PYRIMIDINE
Instrument  : SHIMADZU-FT-IR 8400-Spectrophotometer ; Frequency range : 4000-400 cm-1
(KBr disc.)
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1 3.81 3 H singlet Ar-OCH3    -
2 3.82 3 H singlet Ar-OCH3    -
3 2.52 3 H singlet Ar-SCH3    -
4 6.88-6.94 4 H multiplet Ar-Hkk’,ll’    -
5 7.00-7.03 2 H doublet Ar-Hjj’ Jji=8.7
6 7.31-7.38 5 H multiplet Ar-Hii’(a,c,e)    -
7 7.44-7.49 2 H triplet Ar-H(b,d)    -
8 7.58-7.60 2 H doublet Ar-Hgg’ Jgf=8.4
9 7.72-7.75 2 H doublet Ar-Hff’ Jfg=7.8
11 7.82 1 H singlet Ar-Hm    -




    (dppm)
 Relative No.
  of protons
Multiplicity Inference    J Value

































Instrumental Standard : TMS; Solvent: CDCl3 ; Instrument : BRUKER Spectrometer (300MHz)








































































































































SYNTHESIS AND BIOLOGICAL EVALUATION OF 6-ARYLIMINO-7,N-
A R Y L - 2 - O X O - 4 - { 1 ' , N - P H E N Y L - 3 ' -[ p - ( M E T H Y LT H I O ) P H E N Y L ]-
PYRAZOL-4 ' -YL}-1 ,2 ,3 ,4 -TETRAHYDRO-THIAZOLIDINO-[4 ,5 -d] -
PYRIMIDINES
[A] Synthesis of 1,N-Phenyl-3-[p-(methylthio)phenyl]-4-formyl pyrazole
See Part-I, Section-I (B).
[B] Synthesis of 2-p-Tolylimino-3-(p-tolyl)-5H-4-thiazolidinone
See Part-VII, Section-(C).
[C] Preparation of 6-(p-methoxyphenylimino-7,N-(p-methoxyphenyl)-2-oxo-
4-{1',N-phenyl-3'-[p-(methylthio)phenyl]-pyrazol-4'-yl}-1,2,3,4-
tetrahydro-thiazolidino-[4,5-d]-pyrimidine
To a solution of 2-(p-methoxyphenylimino)-3-(p-methoxyphenyl)-5H-4-
thiazolidinone(3.28 gm, 0.01 mol), 1,N-phenyl-3-[p-(methylthio)phenyl]-4-formyl
pyrazole (2.94 gm, 0.01 mol) and urea (0.60 gm, 0.01 mol) were taken in methanol
(30 ml) and a catalytic amount of con. HCl (0.5 ml) was added. The reaction mixture
was refluxed on water bath for 5 hrs. The content were cooled and poured into
water. The solid thus obtained was filtered and crystallized from dioxane. Yield,
62%, m.p. 183oC; Anal. Calcd. for C35H28N6O3S2, Required : C, 65.20; H, 4.38;
N, 13.03%; Found :  C, 65.18; H, 4.34; N, 13.01 %.
Similarly other 6 - a ry l imino-7 ,N-a ry l -2 -oxo-4 -{1 ' ,N-pheny l -3 ' - [ p -
(methylthio)phenyl]-pyrazol-4 ' -yl}-1,2,3,4-tetrahydro-thiazolidino-[4,5-d]-
pyrimidines were prepared. The physical data are recorded in Table No. 11.
[C] Antimicrobial activity of 6-Arylimino-7,N-aryl-2-oxo-4-{1',N-phenyl-3'-
[p-(methylthio)phenyl]-pyrazol-4'-yl}-1,2,3,4-tetrahydro-thiazolidino-
[4,5-d]-pyrimidines
Antimicrobial testing was carried out as described in Part-I, Section-I (D).
The zone of inhibition of the test solutions are recorded in Graphical Chart No. 11.
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SYNTHESIS AND BIOLOGICAL EVALUATION OF 6-ARYLIMINO-7,N-
A R Y L - 2 - T H I O - 4 - { 1 ' , N - P H E N Y L - 3 ' -[ p- (METHYLT H I O ) P H E N Y L ]-
PYRAZOL-4 ' -YL}-1 ,2 ,3 ,4 -TETRAHYDRO-THIAZOLIDINO-[4 ,5 -d] -
PYRIMIDINES
Thiopyrimidines represent one of the most active class of compounds
possessing a wide spectrum of biological activities, such as significant in vitro  activity
against unrelated DNA and RNA viruses including Polio and Herpes viruses, diuretic,
antitubercular spermidical etc. These valid observation led us to synthesize
thiopyrimidines of type (XII) by condensation of 1,N-phenyl-3-[p-(methylthio)
phenyl]-4-formyl pyrazole with different thiazolidinones and thiourea in presence
of HCl as catalyst.
The constitution of the synthesized products have been characterized by using
elemental analyses, infrared and 1H-nuclear magnetic resonance spectroscopy and
further supported by mass spectroscopy.
All the products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains
and antifungal activity towards Aspergillus niger at a concentration of 40 µg/ml.
The biological activities of the synthesized compounds were compared with standard




























Type-(XII)     R = Aryl




Alkane C-H str. (asym.) 2922 2975-2950    99
-CH3 C-H str. (sym.) 2852 2880-2860     , ,
C-H i.p.def. (asym.) 1440 1470-1435     , ,
C-H o.o.p. (def) 1350 1395-1370     , ,
Aromatic C-H  str. 3028 3090-3030   100
C=C str. 1529 1540-1480     , ,
C-H i.p.def. (asym.) 1095 1070-1000     , ,
C-H o.o.p. (def) 823 835-810     , ,
Pyrazole C=N str. 1600 1600-1650   100
moiety C-N str. 1236 1220-1020     , ,
Pyrimidine C=S str. 729 750-700     , ,
ring N-H str. 3427 3500-3350     , ,
C-N str. 1633 1650-1550     , ,
C-S-C str. 756 800-700     , ,
Ether C-S-C str. (asym.) 1251 1275-1200    99
C-S-C str. (sym.) 1012 1075-1020     , ,
Type     Ref.
        Reported
















































IR SPECTRAL STUDIES OF 6 -(p-TOLYLIMINO)-7,N-(p-TOLYL)-2-
THIO-4-{1',N-PHENYL-3'-[ p-(METHYLTHIO)PHENYL]-PYRAZOL-4'-
YL}-1,2,3,4-TETRAHYDRO-THIAZOLIDINO-[4,5-d]-PYRIMIDINE
Instrument  : SHIMADZU-FT-IR 8400-Spectrophotometer ; Frequency range : 4000-400 cm-1
(KBr disc.)
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1 2.36 3 H singlet Ar-CH3     -
2 2.41 3 H singlet Ar-CH3     -
3 2.52 3 H singlet Ar-SCH3     -
4 6.87-6.89 2 H doublet Ar-Hkk’ Jkl=8.1
5 7.16-7.19 2 H doublet Ar-Hii’ Jij=8.1
6 7.34-7.38 7 H multiplet Ar-Hgg ’ff ’ae,c     -
7 7.46-7.51 2 H triplet Ar-H(b,d)     -
8 7.58-7.61 2 H doublet Ar-Hl,l’ Jlk=8.1
9 7.73-7.76 2 H doublet Ar-Hj,j’ Jji=8.1
10 7.82 1 H singlet Ar-NH     -




    (dppm)
 Relative No.
  of protons
Multiplicity Inference    J Value






























NMR SPECTRAL STUDIES OF 6 - (p-TOLYLIMINO)-7,N-(p-TO LY L ) - 2 -
THIO-4-{1',N-PHENYL-3'-[p-(METHYLTHIO)PHENYL]-PYRAZOL-4'-YL}-
1,2,3,4-TETRAHYDRO-THIAZOLIDINO-[4,5-d]-PYRIMIDINE
Instrumental Standard : TMS; Solvent: CDCl3 ; Instrument : BRUKER Spectrometer (300MHz)










































































































































SYNTHESIS AND BIOLOGICAL EVALUATION OF 6-ARYLIMINO-7,N-
A R Y L - 2 - T H I O - 4 - { 1 ' , N - P H E N Y L - 3 ' -[ p- (METHYLT H I O ) P H E N Y L ]-
PYRAZOL-4 ' -YL}-1 ,2 ,3 ,4 -TETRAHYDRO-THIAZOLIDINO-[4 ,5 -d] -
PYRIMIDINES
[A] Preparation of 2-p-Tolylimino-3-p-tolyl-5H-4-thiazolidinone
See, Part-VII, Section-I (C)
[B] Preparation of 6-Tolylimino-7,N-(p-tolyl)-2-thio-4-{1',N-phenyl-3'-[p-
(methylthio)phenyl]-pyrazol-4'-yl}-1,2,3,4-tetrahydro-thiazolidino-
[4,5-d]-pyrimidine
A mixture of 2-(p-tolylimino)-3-(p-tolyl)-5H-4-thiazolidinone(2.96 gm, 0.01
mol), 1,N-phenyl-3-[p-(methylthio)phenyl]-4-formyl pyrazole (2.94 gm, 0.01 mol)
and thiourea (0.76 gm, 0.01 mol) were taken in methanol (30 ml) and a catalytic
amount of con. HCl (0.5 ml) was added. The reaction mixture was refluxed on
water bath for 6 hrs. The content were cooled and poured into water. The solid thus
obtained was filtered and product was crystallized from dioxane. Yield, 58%, m.p.
162oC; Anal. Calcd. for C35H28N6S3, Required : C, 66.64; H, 4.79; N, 13.36%;
Found :  C, 66.62; H, 4.76; N, 13.32 %.
Similarly other 6 - a ry l imino-7 ,N-ary l -2 - th io -4-{1 ' ,N-phenyl -3 ' - [ p -
(methylthio)phenyl]-pyrazol-4 ' -yl}-1,2,3,4-tetrahydro-thiazolidino-[4,5-d]-
pyrimidines were prepared. The physical data are recorded in Table No. 12.
[C] Antimicrobial activity of 6-Arylimino-7,N-aryl-2-thio-4-{1',N-phenyl-
3'-[p-(methylthio)phenyl]-pyrazol-4'-yl}-1,2,3,4-tetrahydro-thiazolidino-
[4,5-d]-pyrimidines
Antimicrobial testing was carried out as described in Part-I, Section-I (D).
The zone of inhibition of the test solutions are recorded in Graphical Chart No. 12.
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    PART - IX
STUDIES ON
IMIDAZOLINONES




The five membered heterocyclic ring system 5-oxo-imidazoline have two
nitrogen atom at 1 and 3-positions and a carbonyl group at 5-position.
The discovery of the 2-substituted-5-imidazolines dates back to the year 1888,
when A. W. Hoffman
1
 for the first time discovered 5-oxo-imidazoline by heating
N’-diacetylethylene diamine in a stream of dry hydrogen chloride. Moreover,  some
compounds were prepared by A. Ladenburg
2
 by the fusion of two equivalents of
sodium acetate with one equivalent of ethylene diamine dihydrochloride.
SYNTHETIC ASPECT
Various methods have been reported for the synthesis of imidazolinones in
literature.
3
 Aminolysis of oxazolone with amine leads to the formation of
imidazolinones which has been reported in literature.
4
1. A. Saxena et al.
5
 have synthesized new imidazolinones (II).
2. Allimony et al.
6
 have synthesized new imidazolinone derivatives by
conventional method.
3. Feng-Jun-Cai et al.
7



























Azalactone reacts with variety of compounds such as water, alcohols, amines
and hydrogen halides. Amides of a -acylamino acryclic acids obtained from the
condensation of azalactone and primary amines can be converted into imidazolinones
as shown in equation (III). The ring closer can be affected under a variety of
conditions. Substituted anilides have been converted to imidazolinone derivatives
by the action of POCl3.
THERAPEUTIC IMPORTANCE
Naphazoline hydrochloride, xylometazoline hydrochloride etc. are various
imidazolinone derivatives which have been used as adrenergic stimulants and
tolazoline and phenotolamine as adrenergic blocking agents. Various imidazolinones
are known to exhibit a broad spectrum of biological activities such as,
1. Anticonvulsant
8,9































(a)          (b)           (c)
R’-NH2, DryC5H5N/Abs. C2H6OH, K2CO3
(III)
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U. Akyoshi et al.
34
 have prepared some new imidazolinone derivatives (IV)
and reported their herbicidal activity. Agrochemical activity of imidazolinones have
been reported by Bascou and co-workers.
35
Moreover Yoneda Naoto et al.
36
 have synthesized imidazolinones as
antihypertensive agent.  R.  C.  Dage et  al .
37
 have documented cardiotonic
imidazolones.  Rossello et al.
38
 have prepared imidazolones as antifungal agent.
Cooper A. B. and co-workers
39
 have found that imidazolones are inhibitors of farnesyl
proteing transferase. Machii Daisuke et al.
40
 have synthesized new imidazolones as
a telomeres inhibitors and antitumor agents. Jean M. R. et al.
41
 have synthesized
imidazolones and tested as antileishmanial agent. Chafiq amdouchi et al.
42
 have
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Irene M. L. et al.
43
 have patented imidazolinones as antireteroviral activity (V).
Xu Zhi-Feng et al.
44
 have synthesized imidazolinones as biological agent.
Farmshow Christopher Geoffrey et al.
45
 and Pilkington et al.
46
 have described and
studied antifungal activity of imidazolinones. L. Joseph Peter and co-workers
47
 have
prepared substituted imidazolinones which inhibited the abnormal cell growth in
human body. Stefama Lauter and co-workers
48
 have isolated imidazoline from
different methods and tested for the treatment of cytokine release. Imidazoline
derivatives have been prepared by Declera-Arthur and co-workers
49
 showing anti-
HIV activity. Ding, Ming-Wu et al.
50
 have prepared novel imidazolines and reported
their antifungal activity.
K. K. Awasthi et al.
51
 (VI) have synthesized some new imidazolinone
derivatives and reported their antimicrobial activity.
Rama Sharma and co-workers
52
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Kolhe Vishnu et al.
53
 have reported anti-AIDS, antibacterial and fungicidal
activity of 5-oxo-imidazolines. B. R. Shah and co-workers
54
 have prepared some
new imidazolines and reported anticancer and anti HIV activity.
With a view to getting better therapeutic agent, it was contemplated to
synthesize imidazolinones to enhance the overall activity of resulting compounds
which have been described as under.

















SYNTHESIS AND BIOLOGICAL EVALUATION OF 1,N-ARYL-2-ALKYL/
ARYL-4-{1',N-PHENYL-3'-[p-(METHYLTHIO)PHENYL]-4'- PYRAZOLYL
METHINO}-IMIDAZOLIN-5-ONES
Imidazolinones represent one of the most active class of compounds having
a wide spectrum of biological activities. With an aim to getting better therapeutic
agent, the preparation of 5-oxo-imidazolines of Type (XIII) have been undertaken
by the condensation of azalactone with different aromatic amines as shown in reaction
scheme.
The constitution of the synthesized products have been characterized by using
elemental analyses, infrared and 1H-nuclear magnetic resonance spectroscopy and
further supported by mass spectroscopy.
All the products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains
and antifungal activity towards Aspergillus niger at a concentration of 40 µg/ml.
The biological activities of the synthesized compounds were compared with standard




















Type-(XIII) R  = Akyl/Aryl
R1 = Aryl
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IR SPECTRAL STUDIES OF 1,N-PHENYL-2-METHYL-4-{1',N-PHENYL-
3 ' - [ p - ( M E T H Y LT H I O ) P H E N Y L ] - 4 ' - P Y R A Z O LY L M E T H I N O } -
IMIDAZOLIN-5-ONE
 Observed
Alkane C-H str. (asym.) 2923 2975-2950 55
-CH3 C-H str. (sym.) 2884 2880-2860  , ,
C-H i.p.def. (asym.) 1411 1470-1435  , ,
Aromatic C-H  str. 3055 3090-3030 56
C=C str. 1527 1540-1480  , ,
C-H o.o.p. (def) 829 835-810  , ,
Pyrazole C=N str. 1585 1600-1650 56
moiety C-N str. 1180 1220-1020  , ,
Imidazole C=O str. 1712 1760-1655 55
ring C=N str. 1662 1650-1580  , ,
C=C str. 2923 2950-2850  , ,
Type     Ref.
        Reported























































Instrument  : SHIMADZU-FT-IR 8400-Spectrophotometer ; Frequency range : 4000-400 cm-1
(KBr disc.)
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1 2.26 3 H singlet Ar-CH3      -
2 2.49 3 H singlet Ar-SCH3      -
3 7.17-7.25 1 H triplet Ar-Hc      -
4 7.35-7.38 2 H doublet Ar-Hgg’ Jgf = 8.2
5 7.39-7.46 3 H multiplet Ar-H(j,k,l)      -
6 7.48-7.50 2 H triplet Ar-H(b,d)      -
7 7.53 1 H singlet Ar-Hn      -
8 7.56-7.59 2 H doublet Ar-H(i,m)      -
9 7.90-7.93 2 H doublet Ar-H(ff ’ ) Jfg = 8.1




    (dppm)
 Relative No.
  of protons
Multiplicity Inference    J Value
    In Hz

























Instrumental Standard : TMS; Solvent: CDCl3 ; Instrument : BRUKER Spectrometer (300MHz)













































































































SYNTHESIS AND BIOLOGICAL EVALUATION OF 1,N-ARYL-2-ALKYL/
ARYL-4-{1',N-PHENYL-3'-[p-(METHYLTHIO)PHENYL]-4'- PYRAZOLYL
METHINO}-IMIDAZOLIN-5-ONES
[A] Synthesis of 1,N-Phenyl-3-[p-(methylthio)phenyl]-4-formyl pyrazole
See Part-I, Section-I (B).
[B] Synthesis  of   2-Methyl-4-[1',N-phenyl-3'-[p-(methylthio)phenyl]-
pyrazolylmethino]-oxazolin-5-one
To a solution of 1,N-Phenyl-3-[p-(methylthio)phenyl]-4-formyl pyrazole (2.94
gm, 0.01 mol), aminoacid (0.01 mol), acetic anhydride (10.2 gm, 0.01 mol) and
sodium acetate (2.46 gm 0.03 mol) was heated on a waterbath for 4-5 hrs. The
resulting solution was poured on to crushed ice, filtered and crystallized from
dioxane. Yield, 65%, m.p. 241oC.
[C] Synthesis of 1,N-p-Chlorophenyl-2-methyl -4-{1',N-phenyl-3'-[p-
(methylthio)phenyl]-4' -pyrazolylmethino}-imidazolin-5-one
To a solution of 2-Methyl-4-[1',N-phenyl-3'-[p-(methylthio)phenyl]-pyrazolyl
methino]-oxazolin-5-one (3.75 gm, 0.01 mol) and aniline (1.27gm, 0.01 mol) in dry
pyridine (25 ml) was refluxed for 12 hrs. on oil bath. The content was poured on to
crushed ice and neutralized with HCl, the isolated product crystallized from dioxane.
Yield 62%, m.p. 268oC; Anal. Calcd. for C27H21ClN4OS ; Requires : C, 66.86; H,
4.36; N, 11.55%; Found : C, 66.82, H, 4.34, N, 11.52%.
Similarly other 1,N-aryl-2-alkyl/aryl-4-{1',N-phenyl-3'-[p-(methylthio)
phenyl]- 4 '-pyrazolylmethino}-imidazolin-5-ones were prepared. The physical
constants are recorded in Table No. 13.
[D] Antimicrobial activity of 1,N-Aryl-2-alkyl/aryl-4-{1',N-phenyl-3'-[p-
(methylthio)phenyl]-4' -pyrazolylmethino}-imidazolin-5-ones
Antimicrobial activity was carried out as described in Part-I, Section-I (D).
The zone of inhibition of the test solutions are recorded in Graphical Chart No. 13
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N
N
S
CH3
N
N
O
R1
R
R R1
T C6H5- -CH3
T 4-Cl-C6H4- -CH3
T 4-NO2-C6H4- -CH3
T C6H5- C6H5-
T 2-CH3-C6H4- C6H5-
T 4-CH3-C6H4- C6H5-
T 2-OCH3-C6H4- C6H5-
T 4-OCH3-C6H4- C6H5-
T 4-F-C6H4- C6H5-
T 4--Cl-C6H4- C6H5-
T 3,4-(Cl)2-C6H3- C6H5-
T 2,6-(Cl)2-C6H3- C6H5-
